Patients whose asthma remains uncontrolled despite treatment may benefit from a new monoclonal antibody that targets an inflammatory cytokine known to be promoted in asthmatic airways, according to data presented at the annual congress of the European Respiratory Society.

Writing in the Sept. 7 issue of the New England Journal of Medicine, researchers reported on a phase 2, randomized placebo-controlled trial of three dosing regimens of subcutaneous tezepelumab, which targets the epithelial cell–derived cytokine thymic stromal lymphopoietin (TSLP). The trial involved 584 patients with uncontrolled asthma, despite treatment with long-acting beta-agonists and medium to high doses of inhaled glucocorticoids.

The investigators found that exacerbation rates were significantly lower for all three doses of tezepelumab, compared with placebo, with an overall 34% reduction in the risk of exacerbation with tezepelumab (N Engl J Med. 2017;377:936-46).

At 70 mg every 4 weeks, exacerbation rates were 61% lower than in the placebo group; at 210 mg every 4 weeks, they were 71% lower; and at 280 mg every 2 weeks, they were 66% lower.

Statins linked to lower death rates in COPD

BY AMY KARON
Frontline Medical News

FROM CHEST • Receiving a statin prescription within a year after diagnosis of chronic obstructive pulmonary disease was associated with a 21% decrease in the subsequent risk of all-cause mortality and a 45% drop in risk of pulmonary mortality, according to the results of a large retrospective administrative database study.

The findings belie those of the recent Simvastatin in the Prevention of COPD Exacerbation (STATCOPE) trial, in which daily simvastatin (40 mg) did not affect exacerbation rates or time to first exacerbation in high-risk COPD patients, wrote Larry D. Lynd, PhD, a professor at the University of British Columbia, Vancouver, and his associates. Their study was observational, but the association between statin use and decreased mortality “persisted across several measures of statin exposure,” they wrote. “Our findings, in conjunction with previously reported evidence, suggest that there may be a specific subtype of COPD patients that may benefit from statin use.” The study appears in the September issue of CHEST (2017;152:486-93).

COPD affects about 12% of adults aged 30
Time to first exacerbation upped // continued from page 1

(P was less than .001 in comparisons between each group and the placebo).

The overall annualized exacerbation rates by week 52 were 0.26 for the 70-mg group, 0.19 for the 210-mg group, and 0.22 for the 280-mg group, compared with 0.67 in the placebo group, regardless of a patient’s baseline eosinophil count. Patients treated with tezepelumab had a longer time to first asthma exacerbation. They also experienced a significantly higher change from baseline in their prebronchodilator forced expiratory volume in 1 second at week 52, when compared with patients on the placebo.

“The observed improvements in disease control in patients who received tezepelumab highlight the potential pathogenic role of TSLP across different asthma phenotypes,” said Dr. Jonathan Corren.
reported Jonathan Corren, MD, of the University of California, Los Angeles, and his coauthors. "... Although TSLP is central to the regulation of type 2 immunity, many cell types that are activated by or respond to TSLP, such as mast cells, basophils, natural killer T cells, innate lymphoid cells, and neutrophils, may play a role in inflammation in asthma beyond type 2 inflammation."

The incidences of adverse events and serious adverse events were similar across all groups in the study. Three serious adverse events – pneumonia and stroke in the same patient and one case of Guillain-Barré syndrome – in patients taking tezepelumab, were deemed to be related to the treatment.

**Tezepelumab ‘most promising’ asthma biologic to date**

Tezepelumab is the first biologic that has a substantial positive effect on two important markers of the inflammation of asthma – namely, blood eosinophil counts and the fraction of exhaled nitric oxide, noted Elisabeth H. Bel, MD, PhD, in an editorial accompanying the New England Journal of Medicine's publication of this study (2017;377:989-91). It appears to be the broadest and most promising biologic for the treatment of persistent uncontrolled asthma to date, said Dr. Bel, of the department of respiratory medicine, Academic Medical Center, the University of Amsterdam.

The observation that tezepelumab reduces the level of both inflammatory markers shows that it hits a more upstream target and that it blocks at least two relevant inflammatory pathways in asthma, she noted. This is likely to be clinically relevant, since simultaneously increased exhaled nitric oxide levels and blood eosinophil counts are related to increased morbidity due to asthma.

The study was supported by tezepelumab manufacturers MedImmune (a member of the AstraZeneca group) and Amgen. Six of the seven authors are employees of MedImmune or Amgen. One author declared support and honoraria from several pharmaceutical companies, one declared a related patent, and five also had stock options in either MedImmune or Amgen.

Dr. Bel declared consultancies and grants from pharmaceutical companies including AstraZeneca.

**VIEW ON THE NEWS**

Vera A. De Palo, MD, MBA, FCCP, comments: The impact of chronic respiratory disease on patients can be burdensome. Therapies seek to reduce this disease’s impact on patients’ lives. The disease burden takes a particularly heavy toll when the response to therapies is less than optimal. Quality of life and health pay the price. The authors of this phase 2 trial advance another possible therapy which may hold promise for patients severely affected by persistent, treatment-resistant asthma.
Most received atorvastatin

Dr. Lynd

COPYRIGHT © 2017 CHEST PHYSICIAN

COPD were prescribed a statin at least once during the subsequent year. These patients had a significantly reduced risk of subsequent all-cause mortality in univariate and multivariate analyses, with hazard ratios of 0.79 (95% confidence interval: 0.68-0.91; P<0.002).

The protective effect of statins held up when the investigators narrowed the exposure period to 6 months after COPD diagnosis and when they expanded it to 18 months. Exposure to statins for 80% of the 1-year window after COPD diagnosis—a proxy for statin adherence—also led to a reduced risk of all-cause mortality, but the 95% confidence interval for the hazard ratio did not reach statistical significance (0.71-1.01; P=0.6).

The most common prescription was for atorvastatin (49%), usually for 90 days (23%), 100 days (20%), or 30 days (15%), the researchers said. While the ‘possibility of the ‘healthy user’ or the ‘healthy adherer’ cannot be ignored,’ they adjusted for other prescriptions, comorbidities, and income level, which should have helped eliminate this effect, they added. However, they lacked data on smoking and lung function assessments, both of which are important confounders and contributors to mortality, they acknowledged.

Despite [its] limitations, the study results are intriguing and in line with findings from other retrospective cohorts, noted Or Kalchm-Dekel, MD, and Robert M. Reed, MD, in an editorial published in CHEST (2017;152:456-7. doi: 10.1016/j.chest.2017.04.156).

How then can we reconcile the apparent benefits observed in retrospective studies with the lack of clinical effect seen in prospective trials, particularly in the in

IN THIS ISSUE

CHEST Physician

Most received atorvastatin

“Localizing chronic inflammation of the airways has long been observed in COPD patients, but there is a growing understanding of systemic inflammation in a subset of patients,” the researchers noted. For example, studies have linked chronic low-level systemic inflammation or elevated C-reactive protein levels with increased risks of severe airway obstruction, other pulmonary outcomes, and adverse cardiovascular events. Such findings prompted experts to suggest that COPD progression results from systemic inflammation, not a “spill over” of pulmonary inflammation, and that statins might help slow or block this process. Although STATCOPE did not support this idea, several prior observational studies did. Inflammation-inhibiting therapy also reduced cardiovascular events and lung cancer in the recent CANTOS trial, which this issue covers on page 7.

To further explore the question, the researchers analyzed linked health databases from nearly 40,000 patients aged 50 years and older who had received at least three prescriptions for an anticholinergic or a short-acting beta agonist in 12 months some time between 1998 and 2007. The first prescription was considered the date of COPD “diagnosis.” The average age of the patients was 71 years; 55% were female.

A total of 7,775 patients (19.6%) who met this definition of incident COPD years and older worldwide and is associated with increased risk of progressive cardiovascular disease and cardiovascular mortality. "Localizing chronic inflammation of the airways has long been observed in COPD patients, but there is a growing understanding of systemic inflammation in a subset of patients,” the researchers noted. For example, studies have linked chronic low-level systemic inflammation or elevated C-reactive protein levels with increased risks of severe airway obstruction, other pulmonary outcomes, and adverse cardiovascular events. Such findings prompted experts to suggest that COPD progression results from systemic inflammation, not a “spill over” of pulmonary inflammation, and that statins might help slow or block this process. Although STATCOPE did not support this idea, several prior observational studies did. Inflammation-inhibiting therapy also reduced cardiovascular events and lung cancer in the recent CANTOS trial, which this issue covers on page 7.

To further explore the question, the researchers analyzed linked health databases from nearly 40,000 patients aged 50 years and older who had received at least three prescriptions for an anticholinergic or a short-acting beta agonist in 12 months some time between 1998 and 2007. The first prescription was considered the date of COPD “diagnosis.” The average age of the patients was 71 years; 55% were female.

A total of 7,775 patients (19.6%) who met this definition of incident COPD years and older worldwide and is associated with increased risk of progressive cardiovascular disease and cardiovascular mortality. “Localizing chronic inflammation of the airways has long been observed in COPD patients, but there is a growing understanding of systemic inflammation in a subset of patients,” the researchers noted. For example, studies have linked chronic low-level systemic inflammation or elevated C-reactive protein levels with increased risks of severe airway obstruction, other pulmonary outcomes, and adverse cardiovascular events. Such findings prompted experts to suggest that COPD progression results from systemic inflammation, not a "spill over" of pulmonary inflammation, and that statins might help slow or block this process. Although STATCOPE did not support this idea, several prior observational studies did. Inflammation-inhibiting therapy also reduced cardiovascular events and lung cancer in the recent CANTOS trial, which this issue covers on page 7.

To further explore the question, the researchers analyzed linked health databases from nearly 40,000 patients aged 50 years and older who had received at least three prescriptions for an anticholinergic or a short-acting beta agonist in 12 months some time between 1998 and 2007. The first prescription was considered the date of COPD “diagnosis.” The average age of the patients was 71 years; 55% were female.

A total of 7,775 patients (19.6%) who met this definition of incident COPD years and older worldwide and is associated with increased risk of progressive cardiovascular disease and cardiovascular mortality. “Localizing chronic inflammation of the airways has long been observed in COPD patients, but there is a growing understanding of systemic inflammation in a subset of patients,” the researchers noted. For example, studies have linked chronic low-level systemic inflammation or elevated C-reactive protein levels with increased risks of severe airway obstruction, other pulmonary outcomes, and adverse cardiovascular events. Such findings prompted experts to suggest that COPD progression results from systemic inflammation, not a "spill over" of pulmonary inflammation, and that statins might help slow or block this process. Although STATCOPE did not support this idea, several prior observational studies did. Inflammation-inhibiting therapy also reduced cardiovascular events and lung cancer in the recent CANTOS trial, which this issue covers on page 7.

To further explore the question, the researchers analyzed linked health databases from nearly 40,000 patients aged 50 years and older who had received at least three prescriptions for an anticholinergic or a short-acting beta agonist in 12 months some time between 1998 and 2007. The first prescription was considered the date of COPD “diagnosis.” The average age of the patients was 71 years; 55% were female.

A total of 7,775 patients (19.6%) who met this definition of incident COPD years and older worldwide and is associated with increased risk of progressive cardiovascular disease and cardiovascular mortality. “Localizing chronic inflammation of the airways has long been observed in COPD patients, but there is a growing understanding of systemic inflammation in a subset of patients,” the researchers noted. For example, studies have linked chronic low-level systemic inflammation or elevated C-reactive protein levels with increased risks of severe airway obstruction, other pulmonary outcomes, and adverse cardiovascular events. Such findings prompted experts to suggest that COPD progression results from systemic inflammation, not a "spill over" of pulmonary inflammation, and that statins might help slow or block this process. Although STATCOPE did not support this idea, several prior observational studies did. Inflammation-inhibiting therapy also reduced cardiovascular events and lung cancer in the recent CANTOS trial, which this issue covers on page 7.

To further explore the question, the researchers analyzed linked health databases from nearly 40,000 patients aged 50 years and older who had received at least three prescriptions for an anticholinergic or a short-acting beta agonist in 12 months some time between 1998 and 2007. The first prescription was considered the date of COPD “diagnosis.” The average age of the patients was 71 years; 55% were female.

A total of 7,775 patients (19.6%) who met this definition of incident COPD years and older worldwide and is associated with increased risk of progressive cardiovascular disease and cardiovascular mortality. “Localizing chronic inflammation of the airways has long been observed in COPD patients, but there is a growing understanding of systemic inflammation in a subset of patients,” the researchers noted. For example, studies have linked chronic low-level systemic inflammation or elevated C-reactive protein levels with increased risks of severe airway obstruction, other pulmonary outcomes, and adverse cardiovascular events. Such findings prompted experts to suggest that COPD progression results from systemic inflammation, not a "spill over" of pulmonary inflammation, and that statins might help slow or block this process. Although STATCOPE did not support this idea, several prior observational studies did. Inflammation-inhibiting therapy also reduced cardiovascular events and lung cancer in the recent CANTOS trial, which this issue covers on page 7.
STATCOPE study? Could it be that both negative and positive studies are “correct”? Prospective studies have thus far not been adequately powered for mortality as an endpoint, said the editorialists, who are both at the pulmonary and critical care medicine division, University of Maryland, Baltimore. This most recent study reinforces the idea that statins may play a beneficial role in COPD, but it isn’t clear which patients to target for therapy. It is unlikely that the findings will reverse recent recommendations by the American College of Chest Physicians and Canadian Thoracic Society against the use of statins for the purpose of prevention of COPD exacerbations, but the suggestion of survival advantage related to statins certainly may breathe new life into an enthusiasm greatly tempered by STATCOPE, they said.

Canadian Institutes of Health Research supported the study. One coinvestigator disclosed consulting relationships with Teva, Pfizer, and Novartis; the others had no conflicts of interest. Neither editorialist had conflicts of interest.

Continued from previous page

CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) was a randomized, double-blind, placebo-controlled trial involving 10,061 patients in 39 countries, all of whom had a previous MI and a chronically high level of systemic inflammation as reflected in a median baseline high-sensitivity C-reactive protein (CRP) level of 4.1 mg/L. Ninety-one percent of participants were on statin therapy, with a median LDL cholesterol of 82 mg/dL when randomized to subcutaneous canakinumab at 50, 150, or 300 mg or to placebo once every 3 months. Canakinumab is a fully human monoclonal antibody targeting IL-1B, a key player in systemic inflammation. The cytokine is activated by the nucleotide-binding oligomerization domain-like receptor protein 3.
The trend for sepsis incidence from 2009 to 2014, “calculated relative to the observed 2014 rates,” was a stable increase of 0.6% per year using the more accurate of two forms of analysis, investigators reported.

The incidence of sepsis was an adjusted 5.9% among hospitalized adults in 2014, with in-hospital mortality of 15%, according to a retrospective cohort study published online Sept. 13 in JAMA.

“Most studies [of sepsis incidence] have used claims data, but increasing clinical awareness, changes in diagnosis and coding practices, and variable definitions have led to uncertainty about the accuracy of reported trends,” wrote Chanu Rhee, MD, of Harvard Medical School, Boston, and his associates (JAMA. 2017 Sep 13. doi: 10.1001/jama.2017.13836).

They used claims-based estimates using ICD-9-CM codes and clinical data from electronic health records (EHRs) to analyze data for more than 2.9 million adults admitted to 409 U.S. academic, community, and federal acute-care hospitals in 2014. The claims-based explicit-codes approach used discharge diagnoses of severe sepsis (995.92) or septic shock (785.52), while the EHR-based, clinical-criteria method included blood cultures, antibiotics, and concurrent organ dysfunction with or without the criterion of a lactate level of 2.0 mmol/L or greater.

The explicit-codes approach produced an increase of 10.3% per year in sepsis incidence from 2009 to 2014, compared with 0.6% per year for the clinical-criteria approach, while in-hospital mortality declined by 7% a year using explicit codes and 3.3% using clinical criteria, Dr. Rhee and his associates reported. “EHR-based criteria were more sensitive than explicit sepsis codes on medical record review, with comparable [positive predictive value]; EHR-based criteria had similar sensitivity to implicit or explicit codes combined but higher [positive predictive value],” they said.

The estimates provided by Dr. Rhee and his associates lead to “a clearer understanding of trends in the incidence and mortality of sepsis in the United States but also a better understanding of the challenges in improving ICD coding to accurately document the global burden of sepsis,” Kristina E. Rudd, MD, of the University of Washington, Seattle, and her associates said in an editorial (JAMA. 2017 Sep 13. doi: 10.1001/jama.2017.13697).

The Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, National Institutes of Health, Department of Veterans Affairs, National Institutes of Health Clinical Center, and National Institute of Allergy and Infectious Diseases funded the study. Three authors received personal fees from private companies or served on advisory boards or as consultants.

Dr. Paul M. Ridker

You would imagine that, if this does become a treatment, physicians will get much better at bringing patients in early when they have signs and symptoms of infection,” the cardiologist continued.

Patients on canakinumab showed significant reductions in incident rheumatoid arthritis, gout, and osteoarthritis. The drug had no kidney or liver adverse events.

Cancer was a prespecified secondary outcome in CANTOS. The investigators saw the trial as an opportunity to test a longstanding hypothesis that inhibiting IL-1B would have a positive impact on lung cancer in particular.

“Smoking, exposure to diesel fuel, inhalation of asbestos or other silicates – these cause inflammation which activates the NLRP3 inflammasome, but in the pulmonary system rather than the arteries,” explained Dr. Ridker, who reported serving as a consultant to Novartis.

An entry requirement in CANTOS was that patients needed to be free of known cancer. During study follow-up, 129 patients were diagnosed with lung cancer. The risk was reduced in dose-dependent fashion with canakinumab: by 39% relative to placebo in the 150-mg group and by 67% in the 300-mg group. Lung cancer mortality was reduced by 77% in the canakinumab 300-mg group.

“I don’t think this is about oncogenesis per se. I think the tumors are already there, but they don’t progress because we’ve altered the tumor’s inflammatory microenvironment,” he continued.

Simultaneous with Dr. Ridker’s presentation in Barcelona, both the atherosclerotic disease findings (N Engl J Med. 2017 Aug 27. doi: 10.1056/NEJMoia1707914) and the cancer findings (Lancet. 2017 Aug 27. doi: 10.1016/S0140-6736(17)32247-X) were published.

bjancin@frontlinemedcom.com

Dr. Paul M. Ridker

You would imagine that, if this does become a treatment, physicians will get much better at bringing patients in early when they have signs and symptoms of infection,” the cardiologist continued.

Patients on canakinumab showed significant reductions in incident rheumatoid arthritis, gout, and osteoarthritis. The drug had no kidney or liver adverse events.

Cancer was a prespecified secondary outcome in CANTOS. The investigators saw the trial as an opportunity to test a longstanding hypothesis that inhibiting IL-1B would have a positive impact on lung cancer in particular.

“Smoking, exposure to diesel fuel, inhalation of asbestos or other silicates – these cause inflammation which activates the NLRP3 inflammasome, but in the pulmonary system rather than the arteries,” explained Dr. Ridker, who reported serving as a consultant to Novartis.

An entry requirement in CANTOS was that patients needed to be free of known cancer. During study follow-up, 129 patients were diagnosed with lung cancer. The risk was reduced in dose-dependent fashion with canakinumab: by 39% relative to placebo in the 150-mg group and by 67% in the 300-mg group. Lung cancer mortality was reduced by 77% in the canakinumab 300-mg group.

“I don’t think this is about oncogenesis per se. I think the tumors are already there, but they don’t progress because we’ve altered the tumor’s inflammatory microenvironment,” he continued.

Simultaneous with Dr. Ridker’s presentation in Barcelona, both the atherosclerotic disease findings (N Engl J Med. 2017 Aug 27. doi: 10.1056/NEJMoia1707914) and the cancer findings (Lancet. 2017 Aug 27. doi: 10.1016/S0140-6736(17)32247-X) were published.

bjancin@frontlinemedcom.com
This advertisement is not available for the digital edition.
Bedside imaging finds best PEEP settings

BY MICHELE G. SULLIVAN
Frontline Medical News

A noninvasive bedside imaging technique can individually calibrate positive end-expiratory pressure settings in patients on extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS), a study showed.

The step-down PEEP (positive end-expiratory pressure) trial could not identify a single PEEP setting that optimally balanced lung overdistention and lung collapse for all 15 patients. But, electrical impedance tomography (EIT) allowed investigators to individually titrate PEEP settings for each patient, Guillaume Franchineau, MD, wrote (Am J Respir Crit Care Med. 2017;196[4]:447-57. doi: 10.1164/rcmm.201605-1055OC).

“We found that EIT could provide individual, noninvasive, real-time, radiation-free lung imaging with reliable global and regional dynamic analyses of the lungs on ECMO,” wrote Dr. Franchineau of the Pierre and Marie Curie University, Paris.

“Using EIT allowed monitoring of the PEEP effect that prevented excessive lung collapse or overdistension … The large variability of EIT-based best compromise PEEP settings … reinforces the notion of an individually tailored approach to mechanical ventilation. Because of the wide diversity of respiratory-system mechanical properties among patients, bedside tools for monitoring mechanical ventilation on ECMO are crucial to achieve this goal.”

The 4-month study involved 15 patients (aged, 18-79 years) who were in acute respiratory distress syndrome for a variety of reasons, including influenza (7 patients), pneumonia (3), leukemia (2), and 1 case each of Pneumocystis, anti-synthetase syndrome, and trauma.

All patients were receiving ECMO with a constant driving pressure of 14 cm H₂O. After verifying that the inspiratory flow was 0 at the end of inspiration, PEEP was increased to 20 cm H₂O (PEEP 20) with a peak inspiratory pressure of 34 cm H₂O. PEEP 20 was held for 20 minutes and then lowered by 5-cm H₂O decrements with the potential of reaching PEEP 0.

The EIT device, consisting of a silicone belt with 16 surface electrodes, was placed around the thorax aligning with the sixth intercostal parasternal space and connected to a monitor. By measuring conductivity and impedance in the underlying tissues, the device generates a low-resolution, two-dimensional image.

The image was sufficient to show lung distension and collapse as the PEEP settings changed. Investigators looked for the best compromise between overdistention and collapsed zones, which they defined as the lowest pressure able to limit EIT-assessed collapse to no more than 15% with the least overdistention.

There was no one-size-fits-all PEEP setting, the authors found. The setting that minimized both overdistention and collapse was PEEP 15 in seven patients, PEEP 10 in six patients, and PEEP 5 in two patients.

At each patient’s optimal PEEP setting, the median tidal volume was similar: 3.8 mL/kg ideal body weight for PEEP 5, 3.9 mL/kg ideal body weight for PEEP 10, and 4.3 mL/kg ideal body weight for PEEP 15.

Respiratory system compliance was also similar among the groups, at 20 mL/cm H₂O, 18 mL/cm H₂O, and 21 mL/cm H₂O, respectively. However, arterial partial pressure of oxygen decreased as the PEEP setting decreased, dropping from 148 mm Hg to 128 mm Hg to 100 mm Hg, respectively. Conversely, arterial partial pressure of CO₂ increased (32-41 mm Hg).

EIT also allowed clinicians to pinpoint areas of distention or collapse. As PEEP decreased, there was steady ventilation loss in the medi-dorsal and dorsal regions, which shifted to the medial-ventral regions.

“Most end-expiratory lung impedences were located in medial-dorsal and medial-ventral regions, whereas the dorsal region constantly contributed less than 10% of total end-expiratory lung impedance,” the authors noted.

“The broad variability of EIT-based best compromise PEEP settings in these patients with severe ARDS reinforces the need to provide ventilation settings individually tailored to the regional ARDS-lesion distribution,” they concluded. “To achieve this goal, EIT seems to be an interesting bedside noninvasive tool to provide real-time monitoring of the PEEP effect and ventilation distribution on ECMO.”

Positive PEEP trial, but questions remain

This first study to examine EIT in patients under extracorporeal membrane oxygenation shows important clinical potential, but also raises important questions, Claude Guerin, MD, wrote in an accompanying editorial. (Am J Respir Crit Care Med. doi: 10.1164/rcmm.201701-0167ed). The ability to titrate PEEP settings to a patient’s individual needs could substantially reduce the risk of lung derecruitment or damage by overdistention.

The current study, however, has limitations that must be addressed in the next phase of research, before this technique can be adopted into clinical practice, noted Dr. Guerin, a pulmonologist at the Hospital de la Croix Rousse, Lyon, France. The 5-cm H₂O PEEP steps may be too large to detect relevant changes, he said.

In several other studies, PEEP was reduced more gradually in 2- to 3-cm H₂O increments. “Surprisingly, PEEP was reduced to 0 cm H₂O in this study, with this step main-

Continued on following page
Doubts about pediatric CAP diagnostic practices

BY THOMAS R. COLLINS
Frontline Medical News

New studies raise doubts on the reliability of physical exam findings in suspected pediatric community-acquired pneumonia cases and on the value of blood cultures in hospitalized pediatric CAP cases.

In one study, 128 cases of suspected CAP in children aged 3 months to 18 years presenting to an ED from July 2013 to May 2016 underwent paired assessments within 20 minutes of each other. Only 3 of 19 exam findings used to diagnose CAP – wheezing, retractions, and respiratory rate – had acceptable levels of inter-rater reliability, with the lower end of the 95% confidence interval at a Fleiss’ kappa value of 0.4 or higher.

Eight exam findings – capillary...
refill time, cough, rhonchi, head bobbing, behavior, grunting, general appearance, and decreased breath sounds – had poor to fair reliability, with a kappa of 0-0.4, the investigators found. These results came from an ongoing prospective cohort study of children with suspected CAP called Catalyzing Ambulatory Research in Pneumonia Etiology and Diagnostic Innovations in Emergency Medicine, or CARPE DIEM.

"The reliability of these findings must be considered in the clinical management and research of children with CAP," said lead author Todd Florin, MD, associate research director in emergency medicine at Cincinnati Children’s Hospital Medical Center.
In a retrospective cohort analysis, researchers found that just 2.5% of 2,568 hospitalized children with CAP who had a blood culture performed actually grew a pathogen. And of the detected pathogens, 82% were susceptible to penicillin. *Streptococcus pneumoniae* accounted for 78% of all the pathogens that were found; it was detected in only 2% of all children who had blood cultures taken. Just 11 children – or 0.43% of the children with a blood culture performed – had growth of a pathogen that was not treatable with penicillin, said lead author Mark Neuman, MD, director of research at Boston Children’s Hospital and his associates (Pediatrics. 2017;140[3]:e20171013).

The analysis was drawn from a cohort of 7,509 children hospitalized from 2007 to 2011, with children with complex chronic conditions excluded. Data for the analysis came from the Pediatric Health Information System Plus database, in which administrative, billing, laboratory, and radiographic information is stored from six tertiary children’s hospitals.

The investigators said that one challenge is that when blood cultures are drawn early in the course of evaluation and treatment, the severity of the child’s CAP might not be apparent, which makes it difficult to know which children would benefit from a blood culture.

The routine performance of blood cultures in these children may not be indicated,” Dr. Neuman and his associates said. “Researchers in future studies should seek to identify the clinical characteristics of children in whom obtaining blood cultures would lead to changes in clinical management, especially when identifying those patients at risk for CAP caused by organisms not susceptible to guideline-recommended, narrow-spectrum antibiotics.”

Both studies were funded by the National Institutes of Health. For the physician exam study, additional funding was provided by individual grants from the Gerber Foundation, the National Center for Research Resources and the National Center for Advancing Translational Sciences, the National Institute for Allergy and Infectious Diseases and the National Institutes of Health, and a Trustee Award from Cincinnati Children’s Hospital Medical Center. For the blood cultures study, individual researchers received funding from the National Institute of Allergy and Infectious Diseases and the Agency for Healthcare Research and Quality. For the physician exam study, no financial disclosures were reported. For the blood cultures study, Anne Blaschke, MD, PhD, reported receiving research funding from and other financial relationships with BioFire Diagnostics.

** VIEW ON THE NEWS

*Susan Millard, MD, FCCP,* comments: This study is important, because it included a large number of children. We have known for a long time that blood cultures are typically not helpful in older infants and children with CAP. The study also reminds me when educating residents and medical students that physical exam won’t necessarily distinguish between bacterial vs viral pneumonias.
Can we stop worrying about the age of blood?

BY CHRISTOPHER L. CARROLL, MD, MS, FCCP

Blood transfusions are common in critically ill patients; two in five adults admitted to an ICU receive at least one transfusion during their hospitalization (Corwin HL, et al. Crit Care Med. 2004;32[1]:39). Recently, there has been a growing concern about the potential dangers involved with prolonged blood storage. Several provocative observational and retrospective studies found that prolonged storage time (ie, the age of the blood being transfused) negatively affects clinical outcomes (Wang D, et al. Transfusion. 2012;52[6]:1184). But now, some newly published trials on blood transfusion practice, including one published in late September 2017 (Cooper DJ, et al. N Engl J Med. Published online, September 27, 2017) seem to debunk much of this literature. Was all of the concern about age of blood overblown?

The appeal of “fresh” blood is intuitive. As consumers, we’re conditioned that the fresher the better. Fresh food tastes best. Carbonated beverages go “flat” over time. The newest iPhone® device is superior to your old one. So, of course, it follows that fresh blood is also better for your health than older blood.

But, in order to have a viable transfusion service, blood has to be stored. Blood is a scarce resource, and blood banks need to keep an adequate supply on hand for expected clinical necessities, as well as for emergencies. Donors can’t be on standby, waiting in the hospital to provide immediate whole blood transfusion. Also, blood needs to be tested for infections and for potential interactions with the patient, and whole blood must be broken down into individual components for transfusion. All of this requires time and storage.

According to the US FDA, blood can safely be stored for up to 42 days, requiring that there be less than 1% hemolysis at the end of storage, and that more than 75% of the red blood cells remain in circulation 24 hours after the transfusion. But some have suggested that these specifications aren’t comprehensive enough, citing studies that have linked prolonged storage to the development of “red blood storage lesion.” Red blood storage lesion has been theorized to have a variety of effects, including altered immunologic response and defective oxygen carrying capacity (Spinella PC, et al. Transfusion. 2011;51[4]:894). But do these changes have clinical implications?

In a randomized study of 100 critically ill adults supported by mechanical ventilation, 50 were randomized to receive “fresh” blood (median storage age 4 days, interquartile range 3-5 days) and 50 were randomized to receive “standard” blood (median storage age 26.5 days, interquartile range 21-36 days) (Kor DJ, et al. Am J Respir Crit Care Med. 2012;185[8]:842). The primary outcome was gas exchange, as prolonged storage of red blood cells could potentially lead to an increased inflammatory response in patients. However, the authors found no difference in gas exchange between the two groups, and there were no differences in immunologic function or coagulation status.

The ABLE (Age of Blood Evaluation) trial was a randomized, blinded trial of transfusion practices in critically ill patients (Lacroix J, et al. N Engl J Med. 2015;372:1410). In 64 centers in Canada and Europe, 2,430 critically ill adults were randomized to receive either “fresh” blood (mean storage age 6.1 ± 4.9 days) or “standard” blood (mean storage age 22.0 ± 8.4 days). The primary outcome was 90-day mortality, with a power of 90% to detect a 5% change in mortality between the two groups. The investigators found no statistically significant difference in 90-day mortality between the “fresh” and “standard” groups (37% vs 35.3%; hazard ratio 1.1; 95% CI 0.9 - 1.2). Additionally, there were no differences in secondary outcomes, including multiorgan system dysfunction, duration of supportive care, or development of nosocomial infections.

The INFORM (Informing Fresh versus Old Red Cell Management) trial was a randomized study of patients hospitalized in six centers in Canada, Australia, Israel, and the United States (Heddle NM, et al. N Engl J Med. 2016;375[2]:1937). A total of 24,736 patients received transfusions with either “fresh” blood (median storage age 11 days) or “standard” blood (median storage age 23 days). The primary outcome was in-hospital death, with a 90% power to detect a 15% lower relative risk. When comparing the 8,215 patients who received “fresh” blood and the 16,521 patients who received “standard” blood, the authors found no difference in mortality between the two groups (9.1% vs 8.8%; odds ratio 1.04; 95% CI 0.95 to 1.14). Furthermore, there were no differences in outcomes in the high-risk subgroups that included patients with cancer, patients in the ICU, and patients undergoing cardiovascular surgery.

A meta-analysis examined 12 trials of patients who received “fresh” blood compared with those who received “older” or “standard” blood (Alexander PE, et al. Blood. 2016;127[4]:400); 5,229 patients were included in these trials, in which “fresh” blood was defined as blood stored for 3 to 10 days and “older” blood was stored for longer durations. There was no difference in mortality between the two groups (relative risk 1.04; 95% CI 0.94 - 1.14), and no difference in adverse events (relative risk 1.02; 95% CI 0.91 - 1.14). However, perhaps surprisingly, “fresh” blood was associated with an increased risk of nosocomial infections (relative risk 1.09; 95% CI 1.00 - 1.18).

And finally, in the recently published TRANSFUSE trial (Cooper DJ, et al. N Engl J Med. Published online, September 27, 2017), 4,994 critically ill adults were randomized by 59 centers in five countries to receive transfusions stored for a short-term (median storage of 11 days) or long-term (median 21 days). Similar to the other three randomized trials, there was no difference in mortality between the two groups at both 90 and 180 days.

So, can we stop worrying about the age of the blood that we are about to transfuse? Probably. Taken together, these studies suggest that differences in the duration of red blood cell storage allowed within current US FDA standards aren’t clinically relevant, even in critically ill patients. At least, for now, the current practices for age of blood and duration of storage appear unrelated to adverse clinical outcomes.

Dr. Carroll is Professor of Pediatrics, University of Connecticut, Division of Critical Care, Connecticut Children’s Medical Center, Hartford, Connecticut.
This advertisement is not available for the digital edition.
Thirdhand smoke shaping up as potential hazard

BY BRUCE JANCIN
Frontline Medical News

DENVER – Thirdhand smoke – the persistent residue that collects on indoor surfaces where people have smoked – is "clearly" a potentially hazardous exposure, John M. Rogers, PhD, said at the annual meeting of the Teratology Society.

"Everyone knows about the hazards of secondhand smoke, which have led to widespread bans on smoking in public spaces. Still, the Centers for Disease Control and Prevention estimates that 58 million nonsmokers in the United States are exposed to secondhand smoke on a regular basis. And where there is secondhand smoke, there is typically exposure to thirdhand smoke as well."

"If you walk into a hotel room you were told is a nonsmoking room and you take one breath and you know it's not nonsmoking, that's thirdhand smoke. Thirdhand smoke is all over the place where smokers have been," explained Dr. Rogers, director of the toxicity assessment division at the Environmental Protection Agency in Research Triangle Park, N.C.

Tobacco smoke contains thousands of chemicals. Among those known to be harmful developmentally are nicotine, tobacco-specific nitrosamines, lead, cadmium, and various reactive molecules. The odiferous thirdhand smoke residue, composed of tobacco-smoke toxins and known cancer-causing agents, adheres to house dust, furniture, carpets, walls, window glass, and other surfaces. It's difficult to remove. Unlike with secondhand smoke, ventilation won't do the job.

The main potential health risk is to young children, who ingest thirdhand smoke by the hand-to-mouth route and skin contact. Thirdhand smoke is a much newer concept than secondhand smoke and has not yet actually been shown to pose a significant health risk. The term "thirdhand smoke" is still unfamiliar to many physicians and the general public. But that is likely to change.

Thirdhand smoke has become an area of intensive research interest, with California leading the way. The Tobacco-Related Disease Research Program, a state agency funded by a tax on the sale of tobacco products, has created a research consortium on thirdhand smoke, with studies underway investigating thirdhand smoke's precise chemical composition.

E-cigarettes most popular among youngest adults

BY RICHARD FRANKI
Frontline Medical News

Over 15% of adults have used electronic cigarettes at some time, and about 3% reported current use when they were surveyed in 2016, according to the Centers for Disease Control and Prevention.

When those numbers are broken down by age group, the youngest adults are the most likely e-cigarette users: 23.5% of those aged 18-24 years had ever vaped and 4.5% were currently vaping either every day or on some days, the CDC reported (MMWR. 2017;66[33]:892).

For adults aged 25-44 years, ever use of e-cigarettes was 21.1% and current use was 4.2%, with adults aged 45-64 years at 13.1% and 2.9% and those aged 65 years and older checking in at 4.5% ever use and 1% current use, based on estimates derived from National Health Interview Survey data.

Prevalence of e-cigarette use among adults by age, 2016

![Prevalence of e-cigarette use among adults by age, 2016](image)

Note: Based on data from the National Health Interview Survey.
Source: MMWR. 2017;66(33):892

E-cigarettes are the most popular among adults aged 18-24 years.
Cytotoxicity, genotoxicity, and true impact on public health (www.trdrp.org).

Concern regarding thirdhand smoke's potential public health impact ramped up in response to a study in which investigators at the University of York (England) measured levels of various tobacco-specific nitrosamines, N-nitrosamines, and nicotine in house dust samples from the homes of smokers. The researchers estimated that years of early-life exposure to these compounds at the levels they detected could result in one excess case of cancer per 1,000 exposed individuals (Environ Int. 2014 Oct;71:139-47).

In addition to his update on thirdhand smoke, Dr. Rogers also touched on other recent tobacco-related developments, including a determination by the Food and Drug Administration that there has been no decline in tobacco use in the last 5 years in adolescents and young adults. While cigarette smoking by young people decreased, this was offset by a large increase in the use of electronic cigarettes and a smaller rise in the use of hookah tobacco. Indeed, e-cigarette use is now about double that of cigarettes among youth.

Also of concern is evidence of a striking socioeconomic disparity in smoking prevalence: Low-education, low-income Americans have far higher tobacco use rates.

"That's pretty alarming," he said. "I think a lot of people in this audience probably don't see a lot of smoking these days, but it's still around."

Dr. Rogers drew attention to updated evidence reviews on the reproductive and developmental effects of smoking contained in the U.S. Surgeon General's voluminous 2014 report on the health consequences of smoking. The report concluded that there is now sufficient evidence to infer a causal relationship between maternal smoking in pregnancy, ectopic pregnancy, and orofacial clefts. The available evidence is "suggestive but not sufficient" to infer causality between maternal smoking in pregnancy and atrial septal defects, clubfoot, gastroschisis, and attention-deficit/hyperactivity disorder and other disruptive behavior disorders.

Dr. Rogers reported having no financial disclosures related to his presentation, which he noted did not necessarily reflect the views and policies of the EPA.

bjancin@frontlinemedcom.com
Respiratory infections linked to celiac disease

BY LORI LAUBACH
Frontline Medical News

The frequency of respiratory infections in the first 2 years of life could distinguish children who will develop celiac disease (CD) from those who will not in those with a family history of CD, according to Renata Auricchio, MD, University of Naples (Italy) Federico II, and her associates.

In a prospective cohort study, 373 newborns from families with at least one relative with CD were recruited. The cumulative incidence of new cases of CD was 6% at 3 years and 13.5% at 5 years of age, the researchers noted. In the first year when no child produced anti–tissue transglutaminase (anti-tTG) antibodies, respiratory infections (upper and lower tract) were more common among the
case patients than among the controls (58% vs. 40%). During the second year, respiratory infections were again more frequent among the case patients than among controls (52% vs. 32%). And in the third year of life when most of the case patients were diagnosed with CD, no clinical event was more frequent in the case patients than in the control group.

In a multivariate analysis, the researchers found that only respiratory infections in the second year of life were associated with a twofold increase in the risk of developing CD (odds ratio, 2.25; \( P = .04 \)). The second variable was respiratory infections in the first year of life, which had a score of 1.58. Results from the stepwise discriminant analysis suggested respiratory infections in the first and second years of life significantly contributed to the index of discrimination between the case patients and the controls.

“In this study, we report that early infections significantly contribute to the risk of developing CD,” Dr. Auricchio and her associates concluded. “It is possible that the exposure to early infection stimulates a genetically predisposed immune profile, which contributes to the switch from tolerance to intolerance to gluten, which is a common food antigen.”

Read the full study in Pediatrics (doi: 10.1542/peds.2016-4102).

llaubach@frontlinemedcom.com
Hospital-led interventions cut hospitalizations

BY BIANCA NOGRADY
Frontline Medical News

Hospital-driven interventions designed to improve management of asthma in children achieved significant reductions in monthly asthma-related hospitalizations and emergency department visits, according to a paper published online Sept. 18 in JAMA Pediatrics. Long-term management of pediatric asthma is challenging, and around 40% of children and adolescents hospitalized with the disease tend to be rehospitalized or revisit the emergency department within 12 months, according to Carolyn M. Kercsmar, MD, of Children’s Hospital Medical Center in Cincinnati, and her coauthors.

“Traditional care models do not adequately address underlying risk factors, propagating disparities...”

This study, initiated by Cincinnati Children’s Hospital Medical Center, involved a range of interventions implemented with inpatients and outpatients and through the community setting, targeting the region’s more than 36,000 children and adolescents with asthma, approximately 13,000 of whom were Medicaid insured. These included a program that gave all patients a 30-day supply of medications, an asthma action plan, and standardized inhaler training; an asthma-specific history and physical examination form prompting assessment of chronic asthma control, severity, and triggers; a home health pathway of up to five in-home nurse visits; and care coordinators who applied interventions such as a risk assessment, education, medication home delivery, collaboration with a Medicaid managed care practitioner, and improved access to community resources.

Over the 5-year study, researchers saw a 41.8% relative reduction in asthma-related hospitalizations – from 8.1 to 4.7 per 10,000 Medicaid patients per month. Asthma-related visits to the ED decreased by 42.4%, from 21.5 to 12.4 per 10,000 Medicaid patients per month, and the percentage of

Continued on following page
Biopsychosocial model can improve pediatric asthma outcomes

Of importance, any future efforts to replicate this work in a patient-centered way should include consideration of how information on asthma management is communicated to and understood by patients. Standard tools such as asthma action plans often contain language and other information that is inaccessible to populations with low health literacy levels. After years of elevated morbidity, the work of Kercsmar et al. is a demonstration of how interdisciplinary care focused within a biopsychosocial model can improve outcomes for vulnerable children. Future efforts to replicate these results in other communities should continue to emphasize this patient-centered, biopsychosocial philosophy, with heightened attention to the challenges that remain for children and families.

Sean M. Frey, MD, and Jill S. Halterman, MD, MPH, are in the department of pediatrics at the University of Rochester (N.Y.) School of Medicine and Dentistry. These comments are taken from an accompanying editorial (JAMA Pediatrics. 2017, Sep 18. doi: 10.1001/jamapediatrics.2017.2609). No conflicts of interest were declared.
FDA approves new therapy for COPD
Three COPD treatments are now available in one inhaler.

BY LUCAS FRANKI  
Frontline Medical News

The Food and Drug Administration has approved Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), a triple therapy inhaler for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients, according to a press release from GlaxoSmithKline and Innoviva.

Trelegy Ellipta combines an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-2 adrenergic agonist into an inhaler meant for once-daily use in people with COPD. Chronic bronchitis and/or emphysema patients are also indicated for treatment. The FDA-approved dosage is 100 mcg of fluticasone furoate, 62.5 mcg of umeclidinium, and 25 mcg of vilanterol.

The most common adverse events associated with Trelegy Ellipta include headache, back pain, dysgeusia, diarrhea, cough, oropharyngeal pain, and gastrointestinal upset. The patient information leaflet contraindicates for people with “severe hypersensitivity to milk proteins.” Trelegy Ellipta is not indicated for people with asthma or acute bronchospasm.

“This approval represents a significant therapeutic convenience for those appropriate patients already on Breo Ellipta, that require additional bronchodilation or for those patients already on a combination of Breo Ellipta and Incruse Ellipta,” Mike Aguiar, CEO of Innoviva said in the press release.

In results supporting the FDA approval, the IMPACT study, a 52-week phase 3 clinical trial including 10,355 COPD patients sponsored by GSK, found that patients receiving Trelegy Ellipta experienced a 25% reduction in moderate to severe exacerbations compared to patients receiving Anoro Ellipta, and a 15% reduction in moderate to severe exacerbations, compared with patients receiving Relvar/Breo Ellipta. Change from baseline FEV₁, change from baseline scores on the St George’s Respiratory Questionnaire, and time to first moderate/severe COPD exacerbation also were improved in the Trelegy Ellipta study group compared to the others.

Small study: Patients prefer microneedle flu vaccine

BY ELI ZIMMERMAN  
Frontline Medical News

Influenza vaccinations given through a microneedle patch (MNP) received higher patient approval compared with traditional inoculation methods, according to a small study funded by the National Institutes of Health.

In a phase 1, randomized, placebo-controlled study, 100 patients between the ages of 18 and 49 years were split into four groups: one given the patch by a health care worker, one instructed to apply the patch at home, one given a vaccine through a traditional intramuscular injection, and one given a placebo.

Of those who took the patch, 70% (33 of 47) preferred the patch to intramuscular injection (The Lancet. 2017 Jun 27. doi: 10.1016/S0140-6736(17)30575-5).

All nonplacebo groups were given Fluvirin, the 2014-2015 licensed trivalent inactivated influenza vaccine, according to the researchers.

Protection against the virus 6 months after vaccination was similar across all groups other than the placebo group: 20-24 (83%-100%) of 24 participants given the patch by a health care worker, 18-24 (75%-100%) of 24 in the group of patients who gave themselves the patch, and 20-25 (80%-100%) of 25 in the injection group having achieved seroprotection against the three influenza strains 6 months after vaccination.

When measuring reactogenicity, the investigators did find more patients (41 of 50) reported cases of pruritus in the microneedle group than in the injection group (4 of 25). However, these cases were mostly mild, while the injection group reported more grade 2 and grade 3 reactions, with grade 4 being the most severe.

There may also be potential for use among pediatric patients, who may be resistant to vaccinations because of the injection method, the researchers noted.

Some of the researchers are employees of Micron Biomedical, a company that manufactures microneedle products, and are listed as inventors on the licensed patents of these products. The investigators reported no other relevant financial disclosures.

Vaccine reduced risk for flu visits by 42%

BY MARY ANN MOON  
Frontline Medical News

Last year’s influenza vaccination reduced the overall risk for flu-related medical visits by 42%, according to the Centers for Disease Control and Prevention.

In an article summarizing influenza activity in the United States during October 2016–May 2017, investigators said that most of the viral strains antigenically characterized at the CDC “were similar to the reference viruses representing the recommended components for the 2016-2017 vaccine.”

In addition, none of the thousands of samples tested showed resistance to the antivirals oseltamivir, zanamivir, and peramivir, said epidemiologist Lenne Blanton, MD, and her associates in the influenza division, National Center for Immunization and Respiratory Diseases in Atlanta.

The 2017-2018 influenza vaccine has been updated to include an additional influenza A (H1N1) component. This change was recommended by the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, based on data from global influenza virologic and epidemiologic surveillance, genetic and antigenic characterization, human serology studies, antiviral susceptibility, and the availability of candidate influenza viruses (MMWR. 2017;66[25]:668-76).

Preliminary data show that, during the 2016-2017 flu season, there were 18,184 laboratory-confirmed, flu-related hospitalizations, for an overall incidence of 65 per 100,000 population, more than double that for the 2015-2017 season (31/100,000). Broken down by age groups, the rates per 100,000 population increased from 44 at ages 0-4 years, 17 at ages 5-17 years, 20 at ages 18-49 years, and 65 at ages 50-64 years, compared with 291 at ages 65 years and older. Finalized estimates of the number of influenza illnesses, medical visits, and hospitalizations averted by vaccination during the 2016-2017 season will be published in December, the investigators said.

VIEW ON THE NEWS

Vera A. De Palo, MD, MBA, FCCP, comments: For our Global Initiative for Chronic Obstructive Lung Disease 3 and 4 patients who have had hospitalizations, the prescription of multiple classes of inhaled medication is common. These patients are often receiving other medications, with complicated regimens. A patient’s medication list can become the time-schedule-map that consumes much of the day. This has significant impact on the patient’s life, finances, and the likelihood of compliance with medications. For those on triple therapy, the approval of this triple-therapy combination inhaler may offer hope for increased compliance with therapy.

“This is the first study to report a comparison of a single inhaler triple therapy with two dual therapies, providing much needed clinical evidence about the ability of a single inhaler triple therapy to reduce exacerbations,” Patrick Vallance, president of R&D at GSK, noted in a press release announcing the results of the IMPACT study.

elz@frontlinemed.com
No increased mortality with readmission declines

BY SHARON WORCESTER  
Frontline Medical News

Concerns that efforts to reduce 30-day hospital readmission rates under the Affordable Care Act’s Hospital Readmission Reduction Program might lead to unintended increases in mortality rates appear to be unfounded, according to a review of more than 6.7 million hospitalizations for heart failure, acute myocardial infarction, or pneumonia between 2008 and 2014.

In fact, reductions in 30-day readmission rates among Medicare fee-for-service beneficiaries are weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge, according to Kumar Dharmarajan, MD, of Yale New Haven (Conn.) Health, and colleagues (JAMA. 2017 Jul 18;318[3]:270-8. doi: 10.1001/jama.2017.8444).

During the study period, a total of 2.96 million hospitalizations for heart failure, 1.2 million for acute MI, and 2.5 million for pneumonia were identified at 5,106 (heart failure), 4,772 (MI), and 5,057 (pneumonia) hospitals.

The findings by Dharmarajan and colleagues are “certainly good news,” Karen E. Joynt Maddox, MD, wrote in an editorial. The study provides support for strategies that hospitals are using to reduce readmissions, and also underscores the importance of evaluating unintended consequences of policy changes such as the Affordable Care Act’s Hospital Readmissions Reduction Program (HRRP), she said (JAMA. 2017 Jul 18;318[3]:243-4).

The study did not address the possibility that attention to reducing readmissions has taken priority over reducing mortality, which could have the unintended consequence of slowing improvements in mortality, she noted, suggesting that for this and other reasons it may be “time to reexamine and reengineer the HRRP to avoid unintended consequences and to ensure that its incentives are fully aligned with the ultimate goal of improving the health outcomes of patients.”

“Only with full knowledge of the advantages and disadvantages of a particular policy decision can policy makers and advocates work to craft statutes and rules that maximize benefits while minimizing harms,” she wrote.

Dr. Joynt Maddox is with Brigham and Women’s Hospital, Boston. She is supported by a grant from the National Heart, Lung, and Blood Institute.
(pneumonia) short-term acute care hospitals, respectively. In January 2008, the mean hospital 30-day risk-adjusted readmission rates (RARRs) and risk-adjusted mortality rates (RAMRs) after discharge were 24.6% and 8.4% for heart failure, 19.3% and 7.6% for acute MI, and 18.3% and 8.5% for pneumonia, respectively, the investigators said.

From 2008 to 2014, the RARRs declined in aggregate across hospitals (−0.053% for heart failure, −0.044% for acute MI, and −0.033% for pneumonia).

“In contrast, monthly aggregate trends across hospitals in 30-day risk-adjusted mortality rates after discharge varied by admitting condition” the investigators said.

For heart failure, acute MI, and pneumonia, there was an increase of 0.008%, a decrease of 0.003%, and an increase of 0.001%, respectively, they said.

The authors work under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures. Dr. Dharmarajan reported serving as a consultant and scientific advisory board member for Clover Health at the time this research was performed. He is supported by grants from the National Institute on Aging and the American Federation for Aging Research, and the Yale Claude D. Pepper Older Americans Independence Center.

sworcester@frontlinemedcom.com
FDA tries to curtail abuse of ‘orphan drug’ program

BY SARAH JANE TRIBBLE, KAISER HEALTH NEWS

The Food and Drug Administration is changing the way it approves orphan drugs after revelations that drugmakers may be abusing a law intended to help patients with rare diseases.

In a blog post Sept. 12, FDA Commissioner Scott Gottlieb, MD, said he wants to ensure financial incentives are granted “in a way that’s consistent with the manner Congress intended” when the Orphan Drug Act was passed in 1983. That legislation gave drugmakers a package of incentives, including tax credits, user-fee waivers, and 7 years of market exclusivity if they developed medicines for rare diseases.

A Kaiser Health News investigation published in January 2017...
found many drugs that now have orphan status aren’t entirely new. Of about 450 drugs that have won orphan approval since 1983, more than 70 were drugs first approved by the FDA for mass-market use. Those include rosuvastatin (Crestor), aripiprazole (Abilify), and adalimumab (Humira), the world’s best-selling drug.

Dr. Gottlieb announced plans to close a loophole that allows manufacturers to skip pediatric testing requirements when developing a common-disease drug for orphan use in children. He also signaled that bigger changes are being considered, announcing a public meeting to explore issues raised by scientific advances, such as the increase in precision medicine and biologics.

“We need to make sure our policies take notice of all of these new challenges and opportunities,” he wrote. Dr. Gottlieb, through his agency, declined multiple requests for interviews.

Over the years, drugmakers have fueled a boom in orphan drugs, which often carry six-figure price tags. Nearly half of the new drugs approved by the FDA are now for rare diseases – even though many of them also treat and are marketed for common diseases.

Dr. Gottlieb became commissioner in May, a few months after three key Republican senators called for a federal investigation into potential abuses of the Orphan Drug Act, and the Government Accountability Office agreed to investigate.

The GAO has yet to begin its investigation, saying it doesn’t expect to start work until late this year, when staff is available. Regardless, in late June, Dr. Gottlieb announced what would be the first in a series of updates that shift the way the FDA handles orphan drugs.

Those include:
• Eliminating a backlog in drug applications for orphan designation or status. Getting a designation is a critical first step if a company wants to win orphan incentives once the drug is approved for treatment use. And, much like the rise in approvals, the requests by companies to get drugs designated with orphan status has also skyrocketed. Dr. Gottlieb said in June that he wanted to get rid of the backlog; his blog post noted the effort was complete. About half of the 200 applications from drugmakers won orphan status.
• Mandating that drugmakers prove their medicine is clinically superior before getting the market exclusivity that comes with orphan drug status. The agency had lost a lawsuit in which a company said it was owed the exclusivity period regardless of whether its medicine was better. And two more lawsuits had been filed by Eagle Pharmaceuticals and United Therapeutics. The FDA Reauthorization Act, which passed in August, made it law that a drug has to be clinically superior to get the incentives.
• Closing the loophole for pediatric orphan drugs by requiring all drugs approved for common adult diseases, like inflammatory bowel disease, undergo pediatric testing when getting approval as a pediatric orphan drug. Pediatric testing is not required for orphan drugs, and Congress recently mandated that orphan drugs for cancer be tested for children. Still, the American Academy of Pediatrics celebrated the proposed change but warned it was only a first step. Bridgette Jones, MD, chair of American Academy of Pediatrics Committee on Drugs,
PRACTICE ECONOMICS

Medicare payments may be lower than promised

BY GREGORY TWACHTMAN
Frontline Medical News

Physicians will likely see a 0.31% uptick in their Medicare payments in 2018 and not the 0.5% promised in the Medicare Access and CHIP Reauthorization Act. Officials at the Centers for Medicare & Medicaid Services were not able to find adequate funding in so-called misvalued codes to support the larger increase, as required by law, according to the proposed Medicare physician fee schedule for 2018.

CMS also failed to hit its misvalued code target in 2016, resulting in a 0.18% across-the-board reduction to the physician fee schedule in 2017 instead of the statutorily promised 0.5% increase.

Other provisions in the proposed Medicare physician fee schedule may be more palatable than the petite pay raise.

The proposal would roll back data reporting requirements of the Physician Quality Reporting System (PQRS), to better align them with the new Quality Payment Program (QPP), and will waive half of penalties assessed for not meeting PQRS requirements in 2016.

“We are proposing these changes based on stakeholder feedback and to better align with the MIPS [Merit-Based Incentive Payment System track of the QPP] data submission requirements for the quality performance category,” according to a CMS fact sheet on the proposed fee schedule.

“This will allow some physicians who opted to report for the 2016 performance period to avoid penalties and better align PQRS with MIPS as physicians transition to QPP,” officials from the American College of Physicians said in a statement.

Other physician organizations said they believed the proposal did not go far enough.

While the reductions in penalties represent a move in the right direction, the [American College of Rheumatology] believes CMS should establish a value modifier adjustment of zero for 2018,” ACR officials said in a statement. “This would align with the agency’s policy to ‘zero out’ the impact of the resource use component of the Merit-based Incentive Payment System in 2019, the successor to the value modifier program. This provides additional time to continue refining the cost measures and gives physicians more time to understand the program.”

The proposed fee schedule also would delay implementation of the appropriate use criteria (AUC) for imaging services, a program that would deny payments for imaging services unless the ordering physician consulted the appropriate use criteria.

The American Medical Association “appreciates CMS’ decision to postpone the implementation of this requirement until 2019 and to make the first year an opportunity for testing and education where consultation would not be required as a condition of payment for imaging services,” according to a statement.

“We also applaud the proposed delay in implementing AUC for diagnostic imaging studies,” ACR said in the statement. “We will be gauging the readiness of our members to use clinical support systems. ... We support simplifying and phasing-in the program requirements. The ACR also strongly supports larger exemptions to the program,” such as physicians in small groups and rural and underserved areas.

The proposed fee schedule also seeks feedback from physicians and organizations on how Medicare Part B pays for biosimilars. Under the 2016 fee schedule, the average sales prices (ASPs) for all biosimilar products assigned to the same reference product are included in the same CPT code, meaning the ASPs for all biosimilars of a common reference product are used to determine a single reimbursement rate.

That CMS is looking deeper at this is being seen as a plus. Biosimilars “tied to the same reference product may not share all indications with one another or the reference product [and] a blended payment model may cause significant confusion in a multitudinous biosimilars market that may include both interchangeable and noninterchangeable products,” the Biosimilars Forum said in a statement. The current situation “may lead to decreased physician confidence in how they are reimbursed and also dramatically reduce the investment in the development of biosimilars and thereby limit treatment options available to patients.”

Both the Biosimilars Forum and the ACR support unique codes for each biosimilar.

“Physicians can better track and monitor their effectiveness and ensure adequate pharmacovigilance in the area of biosimilars” by employing unique codes, according to ACR officials.

The fee schedule proposal also would expand the Medicare Diabetes Prevention Program (DPP), currently a demonstration project, taking it nationwide in 2018. The proposal outlines the payment structure and supplier enrollment requirements and compliance standards, as well as beneficiary engagement incentives.

Physicians would be paid based on performance goals being met by patients, including meeting certain numbers of service and maintenance sessions with the program as well as achieving specific weight-loss goals. For beneficiaries who are able to lose at least 5% of body weight, physicians could receive up to $810. If that weight-loss goal is not achieved, the most a physician could receive is $125, according to a CMS fact sheet. Currently, DPP can only be employed via office visit; however, the proposal would allow virtual make-up sessions.

“The new proposal provides more flexibility to DPP providers in supporting patient engagement and attendance and by making performance-based payments available if patients meet weight-loss targets over longer periods of time,” according to the AMA.

The fee schedule also proposes more telemedicine coverage, specifically for counseling to discuss the need for lung cancer screening, including eligibility determination and shared decision making, as well as psychotherapy for crisis, with codes for the first 60 minutes of intervention and a separate code for each additional 30 minutes. Four add-on codes have been proposed to supplement existing codes that cover interactive complexity, chronic care management services, and health risk assessment.

For clinicians providing behavioral health services, CMS is proposing an increased payment for providing face-to-face office-based services that better reflects overhead expenses.

Comments on the fee schedule update were due Sept. 11. The final rule is expected in early November.

gtwachtman@frontlinemedcom.com

Continued from previous page

said Sept. 12 that orphan drugs are “still mostly exempt from pediatric study requirements … children deserve access to safe, effective medications.”

Martin Makary, MD, who wrote a critical 2015 paper on orphan approvals, said the changes at the agency indicate that Dr. Gottlieb seems “concerned about all the right things. The government does a lot of lip service in general. This is not lip service.”

The restructuring has been swift in some ways.

Sandra Heibel, PhD, a senior consultant at Hafner Associates, a firm that helps companies submit orphan drug applications, noted that the approval process for designations definitely sped up over the summer, and “we are absolutely getting responses from the FDA back in 90 days. That has come through.”

Other changes to the agency, though, will evolve slowly. For example, the orphan drug office has begun reaching across the FDA’s divisions for help in reviewing drugs. In May, the FDA’s orphan reviews began to work with the office of pediatric therapeutics to review pediatric applications – ideally increasing the expertise applied when considering a company’s request for orphan drug use in children.

In an interview, FDA confirmed that Dr. Gottlieb’s orphan modernization plan is part of a larger effort to increase competition and decrease drug prices. One focus is on targeted drugs – especially those that affect rare diseases or diseases for which there is no effective therapy, the agency said.

“Such drugs present some of the biggest opportunities in medicine to treat and cure debilitating and very costly diseases,” the agency stated.

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.
Hurricane Harvey tests hospital teams’ mettle

BY ELI ZIMMERMAN
Frontline Medical News

As Houston-area citizens evacuated or hunkered down at home in anticipation of Hurricane Harvey, doctors like Mary L. Brandt, MD, packed a bag and headed to work.

“I came in on Saturday morning [Aug. 23] – I was on call – and so I packed a big suitcase and a big bag of food because I anticipated I would be here until Thursday,” Dr. Brandt said in an interview, “So I became part of the ‘ride-out crew.’”

Hospitals were hit hard by Hurricane Harvey, and many struggled against the effects of the Category 4 storm, which made landfall then stalled over Texas for almost a week, pummeling the area.

Preparations began well before the hurricane arrived. As weather experts and government officials warned of the storm’s imminent arrival, Houston’s Texas Children’s Hospital wasted no time making necessary plans in addition to the safeguards their facilities already had in place, Dr. Brandt said.

“We all know this [flooding] could happen, so all the facilities in the medical center have flood gates, and generators are out of the basement so that there is not any risk of losing all electricity, but then the issue becomes the staff,” Dr. Brandt said. “They can’t get to and from the facility, and that’s particularly true if they live in the periphery of Houston, which is common.”

The situation was the same for many area hospitals. Just 2 miles away from Texas Children’s Hospital, SreyRam Kuy, MD, associate chief of staff at the Michael E. DeBakey VA Medical Center, and her colleagues prepared to run the hospital with a skeleton crew.

“We were preparing when it was still a tropical storm, and we talked to the staff ahead of time to let them know this would be a marathon, not a sprint,” Dr. Kuy said in an interview. “We had people staying in the hospital ahead of time because we were worried that when the hurricane hit, we would not be able to have people return.”

But when Harvey made landfall with Category 4 intensity, many medical facilities were caught by surprise.

“We didn’t know how bad it would be, I honestly don’t think anyone in the city or the state had any idea of how tremendous the impact would be, particularly with the flooding,” Dr. Kuy said. “We had staff going 5, 6 days here at the hospital, working continuously, sleeping on the floor, and because of that, we were able to perform multiple emergency surgeries during the disaster, including laparoscopic treatment of ruptured appendicitis and replacement of an infected aortic graft, which required massive transfusion.” The VA hospital broke from its core mission of caring for veterans, treating “homeless folks and nonveterans who were brought here by the Coast Guard, or the ambulances, or by air.”

At Texas Children’s Hospital, Dr. [Continued on page 34]
Brandt and her colleagues were dealing with similar situations, staying on their feet and moving quickly as rescued patients arrived by air. “We were near the area that was flooding really terribly, and so the Coast Guard had been coming in and bringing kids,” Dr. Brandt said. “Sometimes, we knew what was coming and sometimes we didn’t. It was pretty much controlled chaos.” Staff shared responsibilities, often taking on tasks far outside their usual roles.

“We didn’t have enough people working the cafeteria, and so, at one point, I put on my hair net, grabbed a ladle, and served in the lunch line,” Dr. Kuy said. Throughout the storm and flooding, medical professionals fought through exhaustion and depleting supplies, all with little or no knowledge of how their own homes and families were faring. “We had people here for so long, and they had no idea what was happening in their own homes,” Dr. Kuy said. “They were watching on the news, seeing the reports and watching their own neighborhoods flooded.”

Dr. Brandt and her colleagues would watch as reports came in of what was happening beyond the hospital walls. “We have some meeting areas, we would watch the weather together and that goes from the janitors to the head of the hospital who was in the hospital with us,” she said. Despite the chaos outside, morale did not waiver for either Dr. Kuy’s or Dr. Brandt’s crew.

“I remember walking throughout the hospital, doing my rounds, checking up on the units. I went to talk with some of the staff nurses, and what struck me was as I walk in I see these big smiles on their faces; I absolutely did not expect that,” Dr. Kuy said. “They had been in the hospital for 5 days; they were exhausted. It just makes me so proud to serve along these kinds of people.”

As travel became possible, Dr. Kuy and other area physicians – as well as volunteers from across the country – began to shift their focus to evacuation shelters, treating ambulatory patients there. “The response has been phenomenal,” said Dr. Kuy. “I met an ER doctor from North Carolina who came to volunteer, we have FEMA [Federal Emergency Management Agency] doctors from all across the state, and then of course, all the people from the different VA [hospitals].”

Pediatricians have sent their support as well, offering time and supplies to help take care of the patients at Texas Children’s Hospital, Dr. Brandt said. At presstime, volunteers were still needed. The Texas Department of State Health Services opened a web portal for volunteer opportunities, and lifted restriction on out-of-state doctors from practicing medicine without state registration.

While there is still much that needs to be done to recover, those on the ground said that they feel an overwhelming feeling of community as people face what will inevitably be a tough road ahead. “Houston has a reputation and a culture of helping neighbors and it has been astounding to watch what’s happening,” said Dr. Brandt. “No matter how tired people are or how stressful any cases are, everyone’s morale stays high.”

ezimmerman@frontlinemedcom.com
On Twitter @eaztweets
Health IT: Cybercrime risks are real

BY ELI ZIMMERMAN
Frontline Medical News

Aging equipment, valuable data, and an improperly trained workforce make health care IT extraordinarily vulnerable to external malefeasance, as demonstrated by the WannaCry virus episode that occurred this spring in the United Kingdom.

Computer hackers used a weakness in the operating system employed by the U.K. National Health Service, allowing the WannaCry virus to spread quickly across connected systems. The ransomware attack locked clinicians out of patient records and diagnostic machines that were connected, bringing patient care to a near standstill.

The attack lasted 3 days until Marcus Hutchins, a 22-year-old security researcher, stumbled onto a way to slow the spread of the virus enough to manage it, but not before nearly 60 million attacks had been conducted, Salim Neino, CEO of Kryptos Logic, testified June 15 at a joint hearing of two subcommittees of the House Science, Space & Technology Committee. Mr. Hutchins is employed by Kryptos Logic.

U.S. officials are keenly aware that a similar attack could happen here. In June, the federally sponsored Health Care Industry Cybersecurity Task Force issued a report on their year-long look at the state of the health care IT in this country. The task force was mandated by the Cybersecurity Act of 2015 and formed in March 2016.

“The health care system cannot deliver effective and safe care without deeper digital connectivity. If the health care system is connected, but insecure, this connectivity could betray patient safety, subjecting them to unnecessary risk,” according to the task force report. “Data collected for the good of patients and used to develop new treatments can be used for nefarious purposes such as fraud, identity theft, supply chain disruptions, the theft of research and development, and stock manipulation. Most importantly, cybersecurity attacks disrupt patient care.”

Specifically, the task force made the following recommendations:

• Define and streamline leadership, governance, and expectations for health care industry cybersecurity.
• Increase the security and resilience of medical devices and health IT.
• Develop the health care workforce capacity necessary to prioritize and ensure cybersecurity awareness and technical capabilities.
• Increase health care industry readiness through improved cybersecurity awareness and education.
• Identify mechanisms to protect research and development efforts and intellectual property from attacks or exposure.
• Improve information sharing of industry threats, weaknesses, and mitigations.

Health care cybercrime is a significant problem in the United States. In 2016, 328 U.S. health care firms reported data breaches, up from 268 in 2015, with a total of 16.6 million Americans affected, according to a report conducted by Bitglass, a security software company. In February 2016, a hospital in California was forced to pay about $17,000 in Bitcoin, an electronic currency that is known to be favored by cybercriminals, to access electronic health records that were held in a similar manner to last month’s attack on the NHS. For physicians, this may seem like someone else’s problem; however, unsafe day-to-day interactions with connected devices and patient EHRs were among the task force’s primary concerns.

For many, creating a safe password or not giving out critical information may seem like common sense, but many physicians are not able or willing to take the time to make sure they are interacting with systems safely, or they are overconfident in their security system, according to task force member Mark Jarrett, MD, senior vice president and chief quality officer at Northwell Health in New York.

“Most physicians now will try to access medical records of their patients who have been in the hospital because that’s good care,” Dr. Jarrett said in an interview.

But they have to recognize that “they cannot give these passwords to other people and they need to make these passwords complex,” noted Dr. Jarrett.

“Phishing” is another concern. In a phishing scam, cybercriminals will pose as a fraudulent institution or individual in order to trick a target into downloading a virus, sending additional valuable information, or even paying money directly to the criminals.

“Physicians checking their emails need to be aware of possible phishing episodes, because they could be infected, and then there is the possibility that infection could be introduced into the system,” Dr. Jarrett said.

“I think the disconnect is [that physicians] are not used to [cybersecurity]. It’s not part of their daily life and they also, up until recently, thought ‘it’s never going to happen to me’.”

Rachel Clarke, MD, is at Oxford (England) University Hospitals NHS Foundation Trust, and Taryn Youngstein, MD, is at Imperial College Healthcare NHS Trust, London. They reported having no relevant financial conflicts of interest. Their remarks were made in a perspective published in the New England Journal of Medicine (doi: 10.1056/NEJMp1706754).
New data update guidance on nonstatin LDL lowering

BY SHARON WORCESTER

Frontline Medical News

The American College of Cardiology Task Force on Expert Consensus Decision Pathways has released a “focused update” for the 2016 ACC Expert Consensus Decision Pathway (ECDP) on the role of nonstatin therapies for LDL cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. The update was deemed by the ECDP writing committee to be desirable given the additional evidence and perspectives that have emerged since the publication of the 2016 version, particularly with respect to the efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors for the secondary prevention of ASCVD, as well as the best use of ezetimibe in addition to statin therapy after acute coronary syndrome.

“This ECDP addresses current gaps in care for LDL-C lowering to reduce ASCVD risk and provides recommendations that build on the evidence base established by the 2013 [American College of Cardiology/American Heart Association] cholesterol guideline,” explained the committee, which was chaired by Donald M. Lloyd-Jones, MD, of Northwestern University, Chicago (J Am Coll Cardiol. 2017. doi: 10.1016/j.jacc.2017.07.745)

The ECDP algorithms endorse the four evidence-based statin benefit groups identified in the 2013 guidelines (adults aged 21 and older with clinical ASCVD, adults aged 21 and older with LDL-C of 190 mg/dL or greater, adults aged 40-75 years without ASCVD but with diabetes and with LDL-C of 70-189 mg/dL, and adults aged 40-75 without ASCVD or diabetes but with LDL-C of 70-189 mg/dL and an estimated 10-year risk for ASCVD of 7.5% or greater) and assume that the patient is currently taking or has attempted to take a statin, they noted.

Among the changes in the 2017 focused update are:

- Consideration of new randomized clinical trial data for the PCSK9 inhibitors evolocumab and bococizumab. Namely, they included results from the cardiovascular outcomes trials FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) and SPIRE-1 and SPIRE-2 (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), which were published in early 2017.
- An adjustment in the ECDP algorithms with respect to thresholds for consideration of net ASCVD risk reduction. The 2016 ECDP thresholds for risk-reduction...
benefit were percent reduction in LDL-C with consideration of absolute LDL-C level in patients with clinical ASCVD, baseline LDL-C of 190 mg/dL or greater, and primary prevention. In patients with diabetes with or without clinical ASCVD, clinicians were allowed to consider absolute LDL-C and/or non-HDL-cholesterol levels. In the 2017 ECDP update, the thresholds are percent reduction in LDL-C with consideration of absolute LDL-C or non-HDL-C levels for patients in each of the four statin benefit groups. This change was based on the inclusion criteria of the FOURIER trial, the ongoing ODYSSEY Outcomes trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), and the SPIRE-2 trial, all of which included non-HDL-C thresholds. “In alignment with these inclusion criteria, the 2017 Focused Update includes both LDL-C and non-HDL-C thresholds for evaluation of net ASCVD risk-reduction benefit when considering the addition of nonstatin therapies for patients in each of the four statin benefit groups” the update explained.

- An expansion of the threshold for consideration of net ASCVD risk-reduction benefit from a reduction of LDL-C of at least 50%, as well as consideration of LDL-C

Continued on following page
less than 70 mg/dL or non-HDL-C less than 100 mg/dL for all patients (that is, both those with and those without comorbidities) who have clinical ASCVD and baseline LDL-C of 70-189 mg/dL. The 2016 ECDP had different thresholds for those with versus those without comorbidities. This change was based on findings from the FOURIER trial and IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Based on consideration of all available evidence, the consensus of the writing committee members is that lower LDL-C levels are safe and optimal in patients with clinical ASCVD due to their increased risk of recurrent events," they said.

- An expanded recommendation on the use of ezetimibe and PCSK9 inhibition. The 2016 ECDP stated that, "if a decision is made to proceed with the addition of nonstatin therapy to maximally tolerated statin therapy, it is reasonable to consider the addition of ezetimibe as the initial agent and a PCSK9 inhibitor as the second agent." However, based on the FOURIER findings, the ongoing ODYSSEY Outcomes trial, and IMPROVE-IT, the 2017 Focused Update states that, if such a decision is made in patients with clinical ASCVD with comorbidities and baseline
LDL-C of 70-189 mg/dL, it is reasonable to weigh the addition of either ezetimibe or a PCSK9 inhibitor in light of "considerations of the additional percent LDL-C reduction desired, patient preferences, costs, route of administration, and other factors." The update also spells out considerations that may favor the initial choice of ezetimibe versus a PCSK9 inhibitor (such as requiring less than 25% additional lowering of LDL-C, an age of over 75 years, cost, and other patient factors and preferences).

- Additional factors, based on the FOURIER trial results and inclusion criteria, that may be considered for the identification of higher-risk patients with clinical ASCVD. The 2016 ECDP included on this list diabetes, a recent ASCVD event, an ASCVD event while already taking a statin, poorly controlled other major ASCVD risk factors, elevated lipoprotein, chronic kidney disease, symptomatic heart failure, maintenance hemodialysis, and baseline LDL-C of at least 190 mg/dL not due to secondary causes. The 2017 update added being 65 years or older, prior MI or non-hemorrhagic stroke, current daily cigarette smoking, symptomatic peripheral artery disease with prior MI or stroke, history of non-MI related coronary revascularization, residual coronary artery disease with at least 40% stenosis in at least two large vessels, HDL-C less than 40 mg/dL for men and less than 50 mg/dL for women, high-sensitivity C-reactive protein greater than 2 mg/L, and metabolic syndrome.

The content of the full ECDP has been changed in accordance with these updates and now includes more extensive and detailed guidance for decision making – both in the text and in treatment algorithms.

Aspects that remain unchanged include the decision pathways and algorithms for the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C less than 190 mg/dL or in those without ASCVD and LDL-C of 190 mg/dL or greater unattributable to secondary causes.

In addition to other changes made for the purpose of clarification and consistency, recommendations regarding bile acid–sequestrant use were downgraded; these are now only recommended as optional secondary agents for consideration in patients who cannot tolerate ezetimibe.

"[These] recommendations attempt to provide practical guidance for clinicians and patients regarding the use of nonstatin therapies to further reduce ASCVD risk in situations not covered by the guideline until such time as the scientific evidence base expands and cardiovascular outcomes trials are completed with new agents for ASCVD risk reduction," the committee concluded.

Dr. Lloyd-Jones reported having no disclosures.

sworcester@frontlinemedcom.com
Rivaroxaban plus aspirin cut cardiovascular events in stable patients

BY MITCHEL L. ZOLER
Frontline Medical News

BARCELONA – Combined treatment with a very low dosage of the anticoagulant rivaroxaban plus low-dose aspirin produced significant cuts in major adverse coronary, cerebral, and peripheral artery disease events with just a modest rise in major bleeding events in patients with stable disease in the COMPASS pivotal, randomized trial with more than 27,000 patients.

The benefits from the rivaroxaban plus aspirin regimen included a statistically significant 24% relative risk reduction in the study’s primary, combined endpoint, and a significant 18% relative risk reduction in all-cause death, compared with a standard regimen of aspirin only, John W. Eikelboom, MD, said at the annual congress of the European Society of Cardiology. In addition, analysis of the net clinical benefit from treatment that took into account both the major adverse cardiovascular events prevented and major bleeding events induced showed that the rivaroxaban-plus-aspirin regimen cut these by a statistically significant 20%, compared with aspirin alone.

Other notable benefits documented by the findings included a statistically significant 42% relative risk reduction for stroke and a statistically significant 46% relative risk reduction in the incidence of major adverse limb events among the roughly one-quarter of enrolled patients who entered the study with evidence of peripheral artery disease.

These risk reductions are similar in magnitude to the secondary-prevention benefits produced by controlling hypertension or dyslipidemia, noted Dr. Eikelboom, a researcher at McMaster University in Hamilton, Ont. “In the future, rivaroxaban will take its place among the other foundational treatments for long-term, secondary prevention,” he predicted in a video interview, available on CHEST Physician’s web site at http://www.mdedge.com/chealthphysician/article/145492/cad-atherosclerosis/video-rivaroxaban-plus-aspirin-cut-cardiovascular.

The COMPASS trial produced “unambiguous results that should change guidelines and the management of stable coronary artery disease,” commented Eugene Braunwald, MD, designated discussant for Dr. Eikelboom’s report. The results are “an important step for thrombocardiology,” said Dr. Braunwald, professor of medicine at Harvard Medical School in Boston.


The Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) trial enrolled 27,395 patients with stable coronary, carotid, or peripheral artery disease, or a combination of two or more of these, at 602 centers in 33 countries. About 90% of enrolled patients had coronary artery disease and 27% had peripheral artery disease. The enrolled patients averaged 68 year old and were an average of 7 years removed from their index arterial event. Randomization assigned patients to receive 2.5 mg rivaroxaban (Xarelto) twice daily plus 100 mg aspirin daily, 3 mg rivaroxaban twice daily, or 100 mg aspirin once daily. The trial stopped early, after an average follow-up of 23 months, because of the overwhelming benefit seen for the rivaroxaban plus aspirin combination. The rivaroxaban-plus-aspirin regimen cut these

VIEW ON THE NEWS
Low-dose rivaroxaban benefits despite increased bleeding

The key message from COMPASS was that, although adding a very low dosage of rivaroxaban to aspirin in patients with stable coronary or peripheral artery disease resulted in a clear increase in major bleeding events, patients received an overall net benefit effective from the combined regimen. The finding that clinches the net benefit from the rivaroxaban plus aspirin combination, compared with aspirin alone, was that the combined regimen produced a statistically significant relative risk reduction of 18% for all-cause mortality. This finding reinforces the idea that the primary outcome was beneficial despite an increase in major bleeding events.

The finding that rivaroxaban plus aspirin produced benefit with a modest increase in bleeding risk in patients with peripheral artery disease (PAD) is especially important because PAD is really difficult to treat. Very few interventions have been previously proven to have a beneficial effect for patients with PAD. It’s very important to find an intervention that can reduce critical limb ischemia events in addition to reducing coronary events, stroke, and overall mortality.

The very low dosage of rivaroxaban used in COMPASS, 2.5 mg twice daily, seems to be a very important part of the study’s design. This dosage appeared to hit the sweet spot of being large enough to reduce events but with a gentle enough anticoagulation effect to avoid a significant increase in fatal, intracerebral, or critical organ bleeds. However, the patients enrolled in COMPASS, like most patients who enter trials, were generally at a lower risk for bleeding complications than we usually see in routine practice in patients with stable coronary or peripheral artery disease. Presuming that the Food and Drug Administration will soon approve the 2.5-mg formulation of rivaroxaban used in COMPASS, clinicians will need to be careful using this regimen on patients at increased risk for bleeding, such as frail or elderly patients with a history of bleeding events or taking other treatments that could increase bleeding risk, such as nonsteroidal anti-inflammatory drugs. In general, clinicians are wary of using treatments that increase bleeding risk, and so they may hesitate to use this combination of rivaroxaban plus aspirin in patients with a high bleeding risk.

The success of the approach used in COMPASS became possible with the introduction of the new oral anticoagulant drugs. Now that this class of agents has been available for a few years, clinicians have grown increasingly comfortable with them, compared with warfarin. When the new oral anticoagulants first came out, many considered them similar to warfarin. Today, there is a better appreciation that these drugs are distinct from warfarin by really causing fewer bleeding complications.

Christopher B. Granger, MD, is a cardiologist and professor of medicine at Duke University in Durham, N.C. He has been a consultant to and has received research support from Bayer and from other drug companies that market new oral anticoagulants. He made these comments in an interview.

Continued on page 46
SYNDROMIC TESTING FROM BIOFIRE:

Improve Laboratory Efficiency.

BioFire's syndromic testing allows you to quickly identify infectious agents that produce similar symptoms in patients. BioFire's innovative PCR technology provides hospitals, clinics, physicians and patients with the results they need in just one hour using any of the FilmArray® Panels: respiratory, blood culture identification, gastrointestinal and meningitis/encephalitis.

- **Fast.** Quick turnaround times and fast answers make your lab an invaluable partner to clinicians.
- **Easy.** With just two minutes of hands-on time, the FilmArray® System is easily used by any tech, on any shift and at any size institution.
- **Comprehensive.** The FilmArray® Panels test for a comprehensive grouping of viruses, bacteria, parasites, yeast and antimicrobial resistance genes associated with a particular syndrome.

To learn how syndromic testing from BioFire can help make YOUR lab more efficient, visit [biofiredx.com](http://biofiredx.com)

Data on file at BioFire Diagnostics.

**Syndromic Testing: The Right Test, The First Time.**
Respiratory • Blood Culture Identification • Gastrointestinal • Meningitis/Encephalitis
aborted, the aspirin-monotherapy arm failed to show any statistically significant benefits, compared with the aspirin-monotherapy control group.

The study’s primary endpoint—the combined rate of cardiovascular disease death, nonfatal stroke, and nonfatal MI—occurred in 4.1% of patients in the rivaroxaban-plus-aspirin group and in 5.4% of patients on aspirin alone. The rate of major bleeding events was 3.1% among patients on rivaroxaban plus aspirin and 1.9% in those who received aspirin only, a 51% relative increase among patients on the dual regimen, but the results showed no statistically significant increase in the rates of fatal bleeds, intracerebral bleeds, or bleeding in other critical organs.

Sonia Anand, MD, a colleague of Dr. Eikelboom’s at McMaster, presented a separate set of analyses that focused on the 7,470 enrolled patients who had been diagnosed at enrollment with peripheral artery disease. In this subgroup, the rivaroxaban-plus-aspirin regimen produced a statistically significant 28% relative risk reduction in the rate of the primary endpoint, compared with the aspirin control group. The dual regimen also produced a statistically significant 46% relative risk reduction in major adverse limb events and a significant 70% relative reduction in the incidence of major lower-extremity amputations, reported Dr. Anand, professor of medicine and director of the vascular medicine clinic at McMaster.

The COMPASS findings follow a 2012 published report from the ATLAS ACS 2-TIMI 51 trial showing that treatment with the same low-dose rivaroxaban regimen plus aspirin and a thienopyridine (clopidogrel or ticlopidine) reduced the same combined triple endpoint by a statistically significant 16%, compared with aspirin and a thienopyridine alone, in patients with a recent acute coronary syndrome event (N Engl J Med. 2012 Jan 5;366[1]:9-19). Despite this evidence, the Food and Drug Administration never approved the 2.5-mg formulation of rivaroxaban, nor did it approve marketing of rivaroxaban for this acute coronary syndrome population. This decision may have been driven in part by a problem with incomplete follow-up of several of the enrolled patients.

The COMPASS results were “very consistent” with the ATLAS ACS 2-TIMI 51 results. noted Dr. Eikelboom. “I think it’s time to look at both trials would allow ‘a treatment strategy that could start early after an acute coronary syndrome event and then extend long term,’” he said.

COMPASS was sponsored by Bayer, which markets rivaroxaban (Xarelto). Dr. Eikelboom has received research support from Bayer and also from Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, Janssen, Pfizer, Portola, and Sanofi. Dr. Anand has received speaking honoraria from several drug companies. Dr. Braunwald had no relevant financial disclosures.

* mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Dr. Sonia Anand
Dr. Eugene Braunwald
Idarucizumab reversed dabigatran completely, rapidly

BY AMY KARON
Frontline Medical News

One IV 5-g dose of idarucizumab completely, rapidly, and safely reversed the anticoagulant effect of dabigatran, according to final results for the first 90 patients enrolled in the Reversal Effects of Idarucizumab on Active

Dabigatran (RE-VERSE AD) study (NCT02104947), noted Dr. Pollack, of Thomas Jefferson University, Philadelphia.

The final RE-VERSE AD cohort included 301 patients with uncontrolled gastrointestinal, intracranial, or trauma-related bleeding and 202 patients who needed urgent procedures. Participants from both groups typically were white, in their late 70s (age range, 21-96 years), and receiving 110 mg (75-150 mg) dabigatran twice daily. The primary endpoint was maximum percentage reversal within 4 hours after patients received idarucizumab, based on diluted thrombin time and ecarin clotting time.

The median maximum percentage reversal of dabigatran was 100% (95% confidence interval, 100%-100%) in more than 98% of patients, and the effect usually lasted 24 hours. Among patients who underwent procedures, intraprocedural hemostasis was considered normal in 93% of cases, mildly abnormal in 5% of cases, and moderately abnormal in 2% of cases, the researchers noted. Seven patients received another dose of idarucizumab after developing recurrent or postoperative bleeding.

A total of 24 patients had an adjudicated thrombotic event within 30 days after receiving idarucizumab. These events included pulmonary embolism, systemic embolism, ischemic stroke, deep vein thrombosis, and myocardial infarction. The fact that many patients did not restart anticoagulation could have contributed to these thrombotic events, the researchers asserted. They noted that idarucizumab had no procoagulant activity in studies of animals and healthy human volunteers.

About 19% of patients in both groups died within 90 days. “Patients enrolled in this study were elderly, had numerous coexisting conditions, and presented with serious index events, such as intracranial hemorrhage, multiple trauma, sepsis, acute abdomen, or open fracture,” the investigators wrote. “Most of the deaths that occurred within 5 days after enrollment appeared to be related to the severity of the index event or to coexisting conditions, such as respiratory failure or multiple organ failure, whereas deaths that occurred after 30 days were more likely to be independent events or related to coexisting conditions.”

Boehringer Ingelheim Pharmaceuticals provided funding. Dr. Pollack disclosed grant support from Boehringer Ingelheim during the course of the study and ties to Daiichi Sankyo, Portola, CSL Behring, Bristol-Myers Squibb/Pfizer, Janssen Pharma, and AstraZeneca. Eighteen coinvestigators also disclosed ties to Boehringer Ingelheim and a number of other pharmaceutical companies. Two coinvestigators had no relevant financial disclosures.

Bad news keeps piling up for Absorb coronary scaffold

BY BRUCE JANCIN
Frontline Medical News

PARIS – Device thrombosis occurred nearly four times more frequently in recipients of the Absorb everolimus-eluting bioresorbable vascular scaffold than with the Xience everolimus-eluting metallic stent during 2 years of prospective follow-up in the randomized AIDA trial.

AIDA (the Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial) was the first randomized trial designed to compare the Absorb scaffold to a drug-eluting metallic stent in a broad patient population reflecting routine real-world clinical practice. The disturbing AIDA finding follows upon earlier serious concerns raised regarding an increased risk of scaffold thrombosis – and the particularly worrisome complication of late thrombosis – in the ABSORB Japan and ABSORB II trials, Joanna J. Wykryzkowska, MD, reported at the annual congress of the European Association of Percutaneous Cardiovascular Interventions.

Importantly, the AIDA investigators could not identify any predictors of increased device thrombosis risk in Absorb recipients other than the device itself. Neither age, presenting symptoms, lesion characteristics, vessel size, cardiovascular risk factors, nor residual percentage stenosis defined a subgroup of scaffold recipients at particularly increased risk for this complication, said Dr. Wykryzkowska of the University of Amsterdam.

The device was approved by the Food and Drug Administration in July 2016. In March 2017 the agency issued a safety alert regarding the Absorb scaffold after release of the 2-year data from the 2,008-patient ABSORB III trial showing a significantly higher rate of target-lesion failure than with the Xience stent. Both devices are marketed by Abbott Vascular.

AIDA was a single-blind multicenter Dutch trial that randomized 1,845 patients undergoing PCI, 55% of whom presented with acute coronary syndrome. About 27% had diabetes, 29% had chronic kidney disease, and 60% had left main coronary artery disease. Patients received an average of 2.8 Absorb devices per patient. No group received an intervention.

The device was approved by the Food and Drug Administration in July 2016. In March 2017 the agency issued a safety alert regarding the Absorb scaffold after release of the 2-year data from the 2,008-patient ABSORB III trial showing a significantly higher rate of target-lesion failure than with the Xience stent. Both devices are marketed by Abbott Vascular.

AIDA was a single-blind multicenter Dutch trial that randomized 1,845 patients undergoing PCI, 55% of whom presented with acute coronary syndrome. About 27% had diabetes, 29% had chronic kidney disease, and 60% had left main coronary artery disease. Patients received an average of 2.8 Absorb devices per patient. No group received an intervention.

Continued on page 52
**CARDIOVASCULAR MEDICINE**

**New-onset AF after AVR did not affect long-term survival**

**BY MARK S. LESNEY**
*Frontline Medical News*

New-onset atrial fibrillation after aortic valve replacement was not an independent risk factor for decreased long-term survival, according to the results of a single-center, retrospective study reported by Ben M. Swinkels, MD, of St. Antonius Hospital, Nieuwegein, and his colleagues in the Netherlands.

Key to this success, however, is restoring normal sinus rhythm before hospital discharge, they said.

In this prospective, longitudinal cohort study, 569 consecutive patients with no history of AF who underwent AVR with or without concomitant coronary artery bypass grafting during 1990-1993 were followed for a mean of 17.8 years (J Thorac Cardiovasc Surg. 2017;154:490-8).

Thirty-day and long-term survival rates were determined in the 241 patients (42%) with and the 328 patients (58%) without new-onset postoperative atrial fibrillation (POAF), which was defined as electrocardiographically documented AF lasting for at least several hours, and occurring after AVR while the patient was still admitted. Standard therapy to prevent new-onset POAF was the use of sotalol in patients who were not on beta-blocker therapy, and continuation of beta-blocker therapy for those who were already on it.

There were no significant differences between the two groups in demographic characteristics. There were also no significant differences between the two groups in operative characteristics, postoperative in-hospital adverse events, and postoperative hospital lengths of stay until discharge home, except for mechanical ventilation time, which was significantly longer in the patients with new-onset POAF (P = .011).

Thirty-day mortality was 1.2% in the patients with POAF, and 2.7% in those without, a non-significant difference. There was no statistically significant difference between the two survival curves. The Kaplan-Meier overall cumulative survival rates at 15 years of follow-up in the patients with new-onset POAF vs. those without were not statistically different (41.5% vs. 41.3%, respectively).

In addition, the 18-year probability of long-term first adverse events, including recurrent AF, transient ischemic attack, ischemic or hemorrhagic stroke, peripheral venous thromboembolism, or major or minor bleeding was not significantly different between the two groups.

**VIEW ON THE NEWS**

**Results contradict previous studies, but can still reassure**

The incidence of atrial fibrillation after valve surgery has been described to be as high as 50%, Manuel J. Antunes, MD, said in an editorial commentary. “The adverse effect on long-term survival may not be related to the short-lived new-onset AF but rather to the underlying pathology associated to the arrhythmia, especially pathology that affects the myocardium, principally in atherosclerotic coronary artery disease,” he wrote. “It is not survival alone, however, that should be cause for concern; AF, even in episodes of limited duration, may result in transient ischemic attacks, ischemic, or hemorrhagic strokes, and peripheral thromboembolism, which is why affected patients should immediately be anticoagulated.” This study, however, is at odds with previously published studies, with opposite conclusions, according to Dr. Antunes. Swinkels and his colleagues suggest that one of the reasons for the discrepancy was the homogeneous character of their series, which consisted almost entirely of patients who had isolated AVR. Dr. Antunes also adds that another important aspect to consider is that the antiarrhythmic drugs used prophylactically or therapeutically for this patient cohort (treated during 1990-1993) are no longer used or have been replaced by new and more efficacious pharmacologic agents.

“This contribution from Swinkels and colleagues reassures us that new-onset AF, common after heart surgery, may have no significant impact on early and late survival if sinus rhythm is effectively and permanently restored early after the onset of the arrhythmia and before the patient’s discharge from the hospital.”

Manuel J. Antunes, MD, of the University Hospital and Faculty of Medicine, Coimbra, Portugal, made these remarks in an invited editorial (J Thorac Cardiovasc Surg. 2017;154:490-1). He reported having nothing to disclose.

**Continued from page 47**

Dry-onset arrhythmia, and 26% of whom had ST-elevation MI. The primary endpoint was target vessel failure, a composite of cardiac death, target vessel MI, or target-vessel revascularization. The 2-year cumulative rate did not differ significantly between the two study arms: 11.7% in the scaffold group and 10.7% in the metallic stent recipients.

However, definite or probable device thrombosis occurred in 3.5% of the scaffold group compared with 0.9% of metallic stent recipients, for a highly significant 3.9-fold increased risk. This was associated with a significantly increased 2-year cumulative risk of MI: 5.5% versus 3.2%.

On the basis of this unsettling finding, coupled with the fact that ABSORB II investigators did not find any instance of very late scaffold thrombosis among 63 patients who remained on dual-antiplatelet therapy (DAPT) continuously for up to 3 years, Dr. Wykrzykowska and her coinvestigators have informed AIDA participants of their treatment assignment. They have also recommended that the ABSORB recipients go on extended DAPT, even though there is no high-grade evidence as yet that this will prevent late scaffold thrombosis or that the drug-induced increased bleeding risk of prolonged DAPT might cancel or perhaps even outweigh the potential protection against device thrombosis.

Dr. Joanna J. Wykrzykowska

Dr. Joanna J. Wykrzykowska

On top of all this, implantation of the scaffold entails a longer procedure time and a greater volume of contrast material.

Discussant Mahmoud Hashemian, MD, observed that, while bioresorbable vascular scaffolds are “physiologically ideal” because – unlike metallic stents – theoretically they leave no permanent implant to impede vasmotion and serve as a nidus for neoatherosclerosis, to date they have shown no real-world benefits over current-generation drug-eluting metallic stents, but only disadvantages.

“This doesn’t mean we have to feel hopeless. I’m not hopeless at all,” said Dr. Hashemian, an interventional cardiologist at Day General Hospital in Tehran. “I’m sure this [bioresorbable scaffolds] will be the future of our stents. But it needs more work. The company tells me they are going to launch a newer one, maybe next year, with thinner struts and more expandability.”

Asked about the likely mechanism of prolonged thrombosis risk with Absorb, Dr. Wykrzykowska was quick to say no one really knows at this point.

“Technique [predilation at a 1:1 balloon-to-artery ratio with an appropriately sized balloon] can obviously improve things in the short term for early events, but I don’t think we understand the biology of late events. We don’t understand the interaction between the device and the vessel. It’s extremely complex,” she said.

AIDA was funded by an unrestricted educational grant from Abbott Vascular. Dr. Wykrzykowska reported receiving consulting and lecture fees from the company.
Preventive upstream therapy curbs atrial fib progression

BY BRUCE JANCIN  
Frontline Medical News

BARCELONA – Aggressive treatment of known risk factors for atrial fibrillation resulted in improved 1-year maintenance of sinus rhythm in patients with recent-onset atrial fibrillation and heart failure in the randomized multicenter RACE 3 trial, Isabelle C. van Gelder, MD, reported at the annual congress of the European Society of Cardiology.

“We now screen for AF, making it possible to catch patients early. That’s what we’ve learned from this trial: If we start treating patients after their first episode of AF and aggressively reduce risk factors for AF, it may help the sinus rhythm. I think that’s an important message: Do not wait too long; start treatment early,” said Dr. van Gelder, professor of cardiology at the University of Groningen (the Netherlands).

She calls the interventional strategy tested in RACE 3 “risk factor-driven upstream therapy.” The four-pronged strategy consisted of statin therapy, a mineralocorticoid receptor antagonist, an ACE inhibitor and/or an angiotensin receptor blocker, and a 9- to 11-week supervised cardiac rehabilitation program emphasizing lifestyle modification through physical training and dietary changes supported by professional counseling to promote adherence.

RACE 3 (Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure 3) was a multicenter, randomized, nonblinded clinical trial including 245 patients with, on average, a 3-month history of AF, a 2-month history of persistent AF, and a 2-month history of mild to moderate heart failure, either with preserved or reduced ejection fraction. All participants received guideline-directed rhythm control and heart failure therapies. In addition, half of participants were randomized to the upstream intervention. Three weeks after enrollment, all patients underwent electrical cardioversion.

The primary outcome was maintenance of sinus rhythm at 1 year as determined by 7-day Holter monitoring analyzed in blinded fashion at a central laboratory. The rate was 75% in the upstream intervention group. They also showed significant reductions in systolic and diastolic blood pressure, N-terminal pro-brain natriuretic peptide, and LDL cholesterol, compared with controls. However, at 1 year, the two groups didn’t differ significantly in body mass index or left atrial volume.

The lack of impact on left atrial volume was disappointing, Dr. van Gelder said.

The RACE 3 trial was supported by the Netherlands Heart Foundation and the Netherlands Heart Institute. Dr. van Gelder reported having no relevant financial interests.

bjancin@frontlinemedcom.com
ESTES PARK, COLO. – A simple walking speed measurement over a 20-foot distance is an invaluable guide to physiologic age as part of individualized decision making about when to stop cancer screening in elderly patients, according to Jeff Wallace, MD, professor of geriatric medicine at the University of Colorado at Denver.

“If you have one measurement to assess ‘am I aging well?’ it’s your gait speed. A lot of us in geriatrics are advocating evaluation of gait speed in all patients as a fifth vital sign. It’s probably more useful than blood pressure in some of the older adults coming into our clinics,” he said at a conference on internal medicine sponsored by the University of Colorado.
Dr. Wallace also gave a shout-out to the ePrognosis cancer-screening decision tool, available free at www.eprognosis.org, as an aid in shared decision-making conversations regarding when to stop cancer screening. This tool, developed by researchers at the University of California, San Francisco, allows physicians to plug key individual patient characteristics into its model, including comorbid conditions, functional status, and body mass index, and then spits out data-driven estimated benefits and harms a patient can expect from advanced-age screening for colon or breast cancer.

Of course, guidelines as to when to stop screening for various cancers are available from the U.S. Preventive Services Task Force, the American Cancer Society, and specialty societies. However, it’s important that nongeriatricians understand the serious limitations of those guidelines. “We’re not guidelines followers in the geriatrics world because the guidelines don’t apply to most of our patients,” he explained. “We hate guidelines in geriatrics because few studies – and no lung cancer or breast cancer trials – enroll patients over age 75 with comorbid conditions.”

Continued on following page
Also, most of these guidelines do not incorporate patient preferences, which probably should be a primary goal. So we're left extrapolating.

Regrettably, though, "it turns out most Americans are drinking the Kool-Aid when it comes to patient preferences. It's amazing how much cancer screening is going on in this country. We're doing a lot more than we should," said Dr. Wallace.

He highlighted a University of North Carolina study of more than 27,000 participants aged 65 years or older in the population-based National Health Interview Survey. Among those deemed at very high risk of mortality within 9 years, 55% of men had recently undergone prostate cancer screening, and 53% of women had recently had a mammogram. Up to 56% of women who underwent a hysterectomy for benign reasons had a Pap test within the previous 3 years. Moreover, more than one-third of women with less than a 5-year life expectancy had a recent mammogram (JAMA Intern Med. 2014 Oct;174[10]:1558-65).

All of that is clearly overscreening. Experts unanimously agree that, if someone is not going to live for 10 years, the person is not likely to benefit from cancer screening. The one exception is lung cancer screening of high-risk patients, where there are data to show that annual low-dose CT screening is beneficial.
in those with even a 5-year life expectancy.

As part of the Choosing Wisely program, the American Geriatric Society has advocated that physicians “don’t recommend screening for breast, colorectal, prostate, or lung cancer without considering life expectancy and the risks of testing, overdiagnosis, and overtreatment.”

That’s where gait speed and ePrognosis come in handy in discussions with patients regarding what they can realistically expect from cancer screening at an advanced age.

The importance of gait speed was highlighted in a pooled analysis of nine cohort studies totaling more than 34,000 community-dwelling adults aged 65 years and older with 6-21 years of follow-up. Investigators at the University of Pittsburgh identified a strong relationship between gait speed and survival. Every 0.1-m/sec made a significant difference (JAMA. 2011 Jan 5;305[1]:50-8).

A gait speed evaluation is simple: The patient is asked to walk 20 feet at a normal speed, not racing. For men age 75, the Pittsburgh investigators found, gait speed predicted 10-year survival across a range of 19%-87%. The median speed was 0.8 m/sec, or about 1.8 mph, so a middle-of-the-pack walker ought to stop all cancer screening by age 75. A fast-walking older man won’t reach a 10-year remaining life

Continued on following page
expectancy until he’s in his early to mid-80s; a slow walker reaches that life expectancy as early as his late 60s, depending upon just how slow he walks. A woman at age 80 with an average gait speed has roughly 10 years of remaining life, factoring in plus or minus 5 years from that landmark depending upon whether she is a faster- or slower-than-average walker, Dr. Wallace explained.

The U.S. Preventive Services Task Force currently recommends colon cancer screening routinely for 50- to 75-year-olds, declaring in accord with other groups that this strategy has a high certainty of substantial net benefit. But the USPSTF also recommends selective screening for those aged 76-85, with a weaker C recommendation (JAMA. 2016 Jun 21;315[23]:2564-75).

What are the practical implications of that recommendation for selective screening after age 75? Investigators at Harvard Medical School and the University of Oslo recently took a closer look. Their population-based, prospective, observational study included 1,355,692 Medicare beneficiaries aged 70-79 years at average risk for colorectal cancer who had not had a colonoscopy within the previous 5 years.

The investigators demonstrated that the benefit of screening colonoscopy decreased with age. For patients aged 70-74, the 8-year risk of colorectal cancer was 2.19% in those who were screened, compared with 2.62% in those who weren't, for an absolute 0.43% difference. The number needed to be screened to detect one additional case of colorectal cancer was 283. Among those aged 75-79, the number needed to be screened climbed to 714 (Ann Intern Med. 2017 Jan 3;166[1]18-26).

Moreover, the risk of colonoscopy-related adverse events also climbed with age. These included perforations, falls while racing to the bathroom during the preprocedural bowel prep, and the humiliation of fecal incontinence. The excess 30-day risk for any adverse event in the colonoscopy group was 5.6 events per 1,000 patients aged 70-74 and 10.3 per 1,000 in 75- to 79-year-olds.

In a similar vein, Mara A. Schonberg, MD, of Harvard Medical School, Boston, has shed light on the risks and benefits of biannual mammographic screening for breast cancer in 70- to 79-year-olds, a practice recommended in American Cancer Society guidelines for women who are in overall good health and have at least a 10-year life expectancy.

She estimated that 2 women per 1,000 screened would avoid death due to breast cancer, for a number needed to screen of 500. But roughly 200 of those 1,000 women would experience a false-positive mammogram, and 20-40 of those false-positive imaging studies would result in a breast biopsy. Also, roughly 30% of the screen-detected cancers would not otherwise become apparent in an older woman’s lifetime, yet nearly all of the malignancies would undergo breast cancer therapy (J Am Geriatr Soc. 2016 Dec;64[12]:2413-8).

Dr. Schonberg’s research speaks to Dr. Wallace.

“It’s breast cancer therapy: It’s procedures; it’s medicalizing the patient’s whole life and creating a high degree of angst when she’s 75 or 80,” he said.

Dr. Wallace reported having no financial conflicts regarding his presentation.
An interview with incoming CHEST President, John Studdard, MD, FCCP

Born and raised in Mississippi, Dr. Studdard says there were four factors that inspired him to become a physician:
1. I have always loved people and working with them, and I always admired the respect that physicians received in my community.
2. We generally enjoy doing what we are pretty good at...I am pretty good at math and science, and these were important components in pre-med curriculum in my day.
3. I am competitive and decided if it was going to be hard to get into medical school, then I wanted to go to medical school.
4. My dad always told me and me that we would be doctors when we grew up, because we were going to be our own boss. I have been in private practice for 36 years, and that is not the case, not if you are doing it right. I obviously love medicine, and my dad was great in that he paid for our education...but he called the shots.

What are some of the biggest challenges you have encountered throughout your career?
Private practice makes you gain more independence and autonomy; you have to become more agile, more efficient, and you have awfully big workloads. However, you give up the academic stimulation of being in an academic center. It is a tough discipline in the private practice of medicine to try to stay up to date. Whether going to the CHEST Annual Meeting, reading our journal CHEST, or looking at CHEST education online products, those of us in the clinical practice of pulmonary, critical care, and sleep medicine are more dependent than any group what our clinical educators write and teach.

How do/did you balance work and your personal life?
We are busy in practice, particularly when taking on volunteer opportunities, and that time comes out of something: time with family, hobbies, it has to come from somewhere. But it is not unique to those of us in medicine. My daughter is a 33-year-old mother to a 20-month-old beautiful granddaughter of ours and is pregnant with another child, and she and her husband both work full time. Our son and his wife also both work and must find ways to balance work/life issues.

So work-life balance, particularly in today's world, is more difficult than ever for everyone. I am blessed that my wife is the daughter of a general surgeon, and she understood a little bit about stressors in a physician's life - sometimes she seems to understand more than others - she is a unique person. Work-life balance is all about priorities - our priority was our family. We spent a ton of time with our children, great vacations, rarely missed a program or ballgame (there were lots of them), and frequently that involved going to work early in the morning, coming home early in the evening, and going back to the hospital to finish up late at night. A lot of being a good parent is being lucky. We either did a lot of things right, or were lucky, or a combination of both, because I think our kids turned out pretty darn well.

What has been your favorite project throughout your involvement with CHEST?
Early in my days as a member of CHEST, a mentor of mine from training at the Mayo Clinic, Dr. Doug Gracey, gave me the opportunity to join the CHEST Government Relations Committee, which he chaired. After a few years, I was given the opportunity to serve as its Chair. We became heavily involved in the tobacco wars, as some people called them. Our Attorney General in Mississippi at the time, Mike Moore, and a plaintiff's attorney in Mississippi, Dick Scruggs, whom I knew from some work I had done from the defense side of asbestos litigation, took a lead role in the Attorney General's Master Settlement - a group of attorney generals suing the tobacco industry (basically, state's Medicaid was suing the tobacco industry for reimbursement of funds). It was a completely different approach. The tobacco industry turned its nose up at it at first - they did not think it had a chance to fly, but it did. CHEST got involved early on, and then a big group of people, including Tobacco Free Kids, the American Cancer Society, and many others in the public health space, got involved. CHEST represented the public health community during part of the negotiations that led to the Attorney General's Master Settlement. We should be very proud of the role CHEST played in this critical public health effort. If I can look back at my time spent in CHEST leadership, and see it as fondly as I do when I look back at my time just being a part of our CHEST Foundation, I will feel incredibly fulfilled.

What made you want to be President of CHEST?
I believe it is always important to give back to the people who gave you something. CHEST has given me a ton over the last 36 years, so giving back to CHEST is easy.

What are you looking forward to as President of CHEST?
On a personal level, I am looking forward to what we are doing right now, meeting new people, and learning from young people.
Because of my background and upbringing, I have a passion for diversity and inclusion; I think we need to continue to talk about, learn about, care about, be open about, and be transparent about diversity of thought, inclusion, and care disparity. The word “diversity” means something different to every person, and for that, we have to have respect.

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?

What are some of the biggest challenges you have encountered throughout your career?
#Winning: Are you in it to win it at CHEST 2017?

CHEST 2017 offers several contests and opportunities to win great prizes! Are you ready to take home the prize?

**CHEST Events App**

**Game: Click Game**

Do you like scavenger hunts? How about prizes? In our CHEST Events app, you will find the game Click filled with a list of photo challenges. To participate, simply log in and earn your challenge badges by submitting photos to your profile. As you complete each challenge throughout the duration of CHEST 2017, your badges will accumulate, and we will award sweet treats to the person(s) with the highest number of badges on the last day of the annual meeting. Winners can stop by the press room, Metro Toronto Convention Centre, Room 706, to collect prizes on Wednesday, November 1, by 2:00 PM local time.

**Rules of participation**

- To participate, you must be a registered attendee on-site at CHEST 2017.
- The contest begins Saturday, October 28 at 12:00 PM EST, and ends Wednesday, November 1, at 10:00 AM EST.
- Prize must be picked up in the Press Room, Room 706, between the hours of 10:00 AM and 2:00 PM, November 1.
- Questions about the Click photo contest should be directed to socialmedia@chestnet.org

**Are you a VITweep?**

Get active on Twitter, and share your latest highlights for #CHEST2017! Sitting in on an interesting session? Having a great time visiting the posters? Let us know! The most active tweeters for the day will receive a special prize!

**Share your selfies!**

See a selfie spot and take advantage of it! We know there’s more to your trip than lectures and keynote speakers, and we want to see it! Throughout the convention center, you’ll find many designated areas to snap and share photos of yourself and colleagues! Be sure to find them all and share your images on Twitter or Instagram using our #CHEST2017 hashtag. We’ll choose our favorite photo of the day and reshare your picture with our social media followers. Don’t miss your chance to be featured!

**Don’t miss out on CHEST Bingo**

Take advantage of one of the many opportunities in the Exhibit Hall during CHEST. Play CHEST Bingo daily, starting Monday, October 30, through Wednesday, November 1, for a chance to win a prize!
How to play:
Find your bingo card in the program guide that you will receive during registration. Get each bingo letter to spell out C-H-E-S-T as you visit each of the five sponsors’ booths. You will then have a chance to win a $75 gift certificate to the CHEST bookstore. There will be a winner drawn every night!

Win an iPad®!
This year, attendees will have the opportunity to win a refurbished iPad for playing one of our Simulation Center’s arcade style GAMEs (Games Augmenting Medical Education). Last year, we gave away 15 refurbished iPad 2s; this year, we hope to give away 30 refurbished iPad 2s! iPads will be awarded for the following:
• One each day for the fastest time on Aspirated!
• One each day for whoever has played the most games and Virtual Patient Tours (VPTs).
• Several for playing the games Peer Pressure and Nodal Nemesis.
Please refer to the program schedule in the CHEST Events app for dates and times of the GAMEs and VPTs.

This advertisement is not available for the digital edition.
Changes to CPT® codes coming January 2018

BY MIKE NELSON, MD, FCCP
CHEST Physician Editorial Board Member

There will be a number of changes to Current Procedural Terminology (CPT®) codes of interest to pulmonary/critical care providers in January 2018. A thorough understanding of these changes is important for appropriate coding and reimbursement for the services described by these codes.

There are two changes in the CPT codes for bronchoscopy involving 31645 and 31646. CPT code 31645 describes a therapeutic bronchoscopy, eg, removal of viscous, copious or tenacious secretions from the airway. It had previously included wording that suggested it was used for abscess drainage, and this has been removed. If a therapeutic bronchoscopy procedure is repeated during the same hospital stay, then CPT code 31646 should be utilized. If a therapeutic bronchoscopy procedure is performed in the non-hospital setting and later repeated, then CPT code 31646 would be used for both procedures. CPT code 94620 Pulmonary stress testing; simple (eg, 6-minute walk test, prolonged exercise test for bronchospasm with pre- and post-spirometry and oximetry) has been deleted and replaced by two new codes. CPT code 94617 Exercise test for bronchospasm, including pre- and postspirometry, electrocardiographic recording(s), and pulse oximetry describes the procedure used to assess for exercise-induced bronchospasm. CPT code 94618 Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed, describes the typical simple pulmonary stress test. After January 1, 2018, if CPT code 94620 is used, the claim will be denied. CPT code 94621 Cardiopulmonary exercise testing, including measurements of minute ventilation, CO₂ production, O₂ uptake, and electrocardiographic recordings has been reworded to better describe the procedure of cardiopulmonary exercise testing. Additionally, there are numerous parentheticals appended that list the CPT codes that may not be used in conjunction with 94617, 94618, and 94621. Please refer to the 2018 CPT manual for further information on these exclusions.

NEW PRESIDENT // continued from page 59

As Dr. Studdard prepares to take on his new role in CHEST leadership this October, he is optimistic about what the future will bring and about the things that he will learn. He considers himself incredibly lucky to be in the position that he is in, and he values each relationship he has made during his involvement with CHEST. He is looking forward to all that is in store during his time as President. He left us with a quote from Wyatt Cooper:

"The only immortality we can be sure of is that part of ourselves we invest in others—the contribution we make to the totality of man, the knowledge we have shared, the truths we have found, the causes we have served, the lessons we have lived."
Transbronchial cryobiopsy, updated guidelines for chronic cough in children, PD-1 inhibition

Interventional Chest/Diagnostic Procedures

Cryobiopsy for ILD: Careful stewardship needed

Interest in transbronchial cryobiopsy has accelerated rapidly in recent years. This procedure is performed by advancing a cryoprobe into the peripheral lung via flexible bronchoscopy, where lung tissue freezes and adheres to the probe and is subsequently extracted as a cryobiopsy. The number of cryobiopsy-related publications has increased exponentially since it was described in 2009 (Babiak A, et al. Respiration. 2009;78[2]:203). This interest stems from reports of high diagnostic yields in patients with interstitial lung disease (ILD) while maintaining complication rates similar to that of conventional bronchoscopic biopsy.

Traditional bronchoscopic biopsies are notoriously insensitive; a specific diagnosis can be established in fewer than a third of cases (Sheth JS, et al. Chest. 2017;151[2]:389). As such, surgical lung biopsy continues to be recommended but is associated with significant mortality (2%) and morbidity (30%) in patients with ILD (Hutchinson JP, et al. ARJCCM. 2016;193[10]:1161). Cryobiopsy, which appears to rival surgical lung biopsy in terms of ability to contribute to a specific diagnosis, is, therefore, a highly promising alternative (Tomassetti S, et al. ARJCCM. 2016;193[7]:745).

As cryobiopsy is increasingly adopted around the world, however, troubling reports of serious complications have surfaced. Most notable is the recently reported experience of the initial 25 cases performed at the University of Pennsylvania, in which almost one in four patients suffered serious complications (DiBardino DM, et al. Ann Am Thorac Soc. 2017;14[6]:851). The authors pointed to lack of a predefined procedural protocol, as well as several choices relating to the specific technique used, including inconsistent use of fluoroscopy, lack of prophylactic bronchial blocker placement, and predominant use of laryngeal mask airways as potential contributing factors. Indeed, many variations of the basic cryobiopsy procedure have been described (Lentz RJ, et al. J Thoracic Dis. 2017;9[7]:2186), with no formal guidance or training available to inform advanced bronchoscopists interested in this procedure.

It is incumbent on the interventional pulmonology and ILD specialist communities to be responsible stewards of this promising procedure. Implementation of three parallel efforts to standardize and rigorously study this procedure should be considered as soon as possible: creation of expert consensus guidelines establishing best-practices for safe and effective biopsy technique; a training requirement before independent performance of the procedure; and creation of an international cryobiopsy registry to facilitate higher-quality research into optimal technique and outcomes. We owe this to our patients.

Robert J. Lentz, MD
NetWork Member
Fabien Maldonado, MD, FCCP
NetWork Member

Pediatric Chest Medicine

Chronic cough in children: New guidelines

A chronic cough is a common complaint among children whose parents seek medical evaluation. Chronic wet cough can indicate an underlying illness; therefore, an early diagnosis can lead to prevention of complications of the disease and improvement in quality of life. CHEST is a leading resource in evidence and consensus-based guidelines on important topics affecting children. The most recent guidelines entitled Management of Children with Chronic Wet Cough and Protracted Bacterial Bronchitis (Chest. 2017;151(4):884-890) and Use of Management Pathways or Algorithms in Children with Chronic Cough (Chest. 2017;151(4):875-873) are updates from the 2006 CHEST guidelines on chronic cough in children.

The present updates utilized the CHEST methodological guidelines with chronic wet or productive cough and Grading of Recommendations Assessment, Development, and Evaluation framework and also performed a systematic review addressing key questions concerning the management of childhood disease for children 14 years and younger.

Guidance provided by the expert panel focused on recommendations to answer six key questions concerning the management of children 14 years and younger with a chronic wet cough unrelated to established chronic lung disease. The recommendations are:

1. Chronic cough is defined as the presence of a cough 4 weeks or longer in duration.
2. Assessment of the effect of the cough on the child and the family should be undertaken as part of clinical consultation.
3. Evaluation of a chronic cough should be done with a systematic approach with pediatric-specific cough management protocols or algorithms.
4. Chest radiograph and, when age appropriate, spirometry with bronchodilator be undertaken as evaluation; tests for pertussis infection only to be performed if clinically suspected.
5. Chronic wet cough with no specific clinical features should receive antibiotics for 2 weeks targeted for common respiratory bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis).
6. When cough persists despite 2 weeks of appropriate antibiotics, it is recommended to continue for an additional 2 weeks.
7. Additional tests (eg skin prick test, Mantoux, bronchoscopy, chest CT scan) should be individualized in accordance with the clinical setting and child’s clinical symptoms and signs.

The panel recognizes the need for prospective studies to assess current algorithms outcomes of children with chronic cough. Both articles can be found on the guidelines section of the CHEST site.

John Bishara, DO
Fellow-in-Training Member

Pulmonary Physiology, Function, and Rehabilitation

Functional imaging of the lung

Quantifying heterogeneity of ventilation and gas exchange in lung diseases remains a clinical challenge. Conventional pulmonary function test is insensitive to regional changes. The multiple inert gas elimination technique can quantify ventilation-perfusion distribution, but it requires invasive instrumentation (eg, pulmonary artery catheterization) and is not practical for clinical use. Computed tomography (CT) scans delineate spatial changes in lung structures but do not directly measure changes in ventilation and gas exchange. With its radiation, it is difficult to apply CT scanning repeatedly in patients. More recently, MR imaging techniques have been developed to directly “visualize” and quantify regional lung function (Kruger S, et al. J Magn Reson Imaging. 2016;43(2):295; Roos JE, et al. Magn Reson Imaging Clin N Am. 2015;23(2):217). These techniques employ inhalation of gases, such as oxygen, perfluorinated gases, and hyperpolarized 3He, and 129Xe. Hyperpolarized 3He has been studied the most; however, the dwindling supply of 3He gas and its rising cost have prevented its further development. 129Xe has abundant supply and has emerged to be the inert gas of choice for MR imaging. Hyperpolarized 129Xe can measure ventilation, like hyperpolarized 3He. In addition, 129Xe diffuses into alveolar barrier (interstitium and plasma) and red blood cells, where it exhibits distinct resonant frequency shifts that can be captured by MR. Therefore, in one test, information on pulmonary ventilation and gas transfer can be obtained. To date, the results from MR imaging studies have provided new insights into the pathophysiology of obstructive

Continued on page 68
Thoracic Oncology

Immune-mediated pneumonitis and PD-1 inhibition

Inhibitors of the programmed cell death 1 receptor (PD-1) have shown significant promise in the treatment of advanced stage malignancy. With the recent expansion of indications for use of these agents, the number of patients treated will continue to grow. Clinicians must be aware of their potential for serious adverse side effects, including dermatitis, colitis, and potentially life-threatening pneumonitis.

The development of pneumonitis secondary to PD-1 inhibitions is reported to occur in 2% to 5% of patients and can present at any time during therapy, with 1% of patients developing grade 3 or higher pneumonitis. The most common symptoms are dyspnea and cough, though one-third

Yuh-Chin T. Huang, MD, MHS, FCCP
Steering Committee Member

Continued from page 63
Continued on page 71
Relief for TBM patients is here. Tracheobronchomalacia, or TBM for short, is a rare lung condition found in people of all ages. Due to its similarities to well-known diseases like emphysema or asthma, this condition often goes undiscovered. And for patients with undiagnosed TBM, finding relief can seem impossible.

Beth Israel Deaconess Medical Center offers advanced treatment for TBM, thanks to the expertise of our amazing team of doctors, including Dr. Sidhu Gangadharan and Dr. Adnan Majid. BIDMC is a world-leader in treating TBM, offering a rare expertise and surgical techniques that are unavailable in most institutions.

To learn more about TBM treatment at BIDMC, call 617-632-8252 or go to bidmc.org/TBM.
Coastal Virginia Opportunities
Outpatient and Inpatient: Pulmonary and Critical Care

Join our 560+ multi-specialty clinical team (RMG) at the heart of one of America’s strongest healthcare delivery organizations - Riverside Health System. It is a system well-prepared to help you face the challenging growth of current and future healthcare demands. Over 100 years old, it has an established reputation for strength in many specialties including neurosciences, cardiac, orthopedic care, elder care, wellness and mental health support. Each role allows you the opportunity to work with highly respected teams offering a variety of cases, collaborative environments and solid referral patterns. Locations include:

• Newport News: hamptonroads.com • Williamsburg: visitWilliamsburg.com
• Gloucester: gloucesterva.info • Tappahannock: essex-virginia.org

Ideal candidates understand and welcome the importance of their roles as care providers, team members, and major influencers of our community’s impression of Riverside’s quality and service. Discover the lifestyle of southeastern Virginia where social and cultural opportunities abound with moderate climate and easy access to the Chesapeake Bay, the majestic James River, and Atlantic Ocean.

Please forward your CV to:
Nicole Laroche, CPC, CERS
Physician Development
Nicole.Laroche@rivhs.com
Office: (757) 224-4990, Cell: (757) 544-6069

Singing River Health System
Pulmonology/Critical Care

Outstanding opportunity for pulmonary critical care on the Mississippi Gulf Coast. This is a well-established group which is hospital employed. Coverage is provided to two hospitals within the system. This group runs the only Pulmonary Hypertension Center on the Mississippi Gulf Coast. Advanced bronchoscopy including EBUS, radial EBUS, and navigational bronchoscopy is available. Additional pulmonary interventions provided by thoracic surgeons. Active Lung Cancer Screening program is operational in the system. AASM accredited sleep center with 6 beds is run by three sleep board certified physicians. Intensivist coverage provided for 24 bed multidisciplinary ICU. Physician extenders are also part of the group and assist in the ICUs and clinic. Visa sponsorship available.

Benefits Available:
• The most competitive incentive package with a guaranteed base plus performance and production incentives
• Relocation Assistance or Sign-on Bonus
• Student Loan Assistance
• Annual CME Allowance
• Annual pledge towards licensure and fees
• Malpractice Coverage
• Paid Time Off per Human Resources policy and procedure

Please forward your CV to: Physician Relations Department,
Christy.Myers@myrvhs.com 228-818-4023 or Krisann.Dikes@myrvhs.com 228-818-4024

Enjoy a Busy Practice with an Exceptional Quality of Life in the “City of Four Seasons” Hendersonville, North Carolina!

Excellent Pulmonary/Critical Care Medicine Physician Practice Opportunity with Carolina Lung and Sleep at Pardee. Sleep Medicine practice optional. Physician must be BC in Pulmonary and Critical Care. Sleep Fellowship/BC required if practice includes Sleep Medicine.

Competitive base + wRVU incentive, annual bonus based on quality measures, comprehensive benefits and retirement package, professional liability insurance, Paid Time Off, sign-on, relocation. Epic EMR.

Pardee Hospital is a 222-bed not-for-profit community hospital affiliated with UNC Health Care. New cancer center adjacent to practice with Hematology/Oncology and Radiation Oncology, clinical trials, registry, and survivorship program. Lung Nodule Clinic under development. Ebus and Navigational Bronchoscopy added in 2015. Beautiful community in the WNC mountains located between Greenville, SC, and Asheville, NC.

No Visa Sponsorships — No Recruitment Firm Inquiries

Send CV for consideration to: Lilly Bonetti
Pardee UNC Health Care
800 North Justice Street
Hendersonville, NC 28791
(828) 694-7687
Lillian.bonetti@unhealth.unc.edu
www.pardeehospital.org

Pulmonary/Critical Care with Sleep
Cambridge Health Alliance • Cambridge, MA

Cambridge Health Alliance (CHA) an award-winning public healthcare system, has an opportunity for a Pulmonary/ Critical Care Physician to join our existing Pulmonary team. Our system is comprised of three hospital campuses and an integrated network of both primary and specialty care practices in the Boston area. CHA is a teaching affiliate of both Harvard Medical School (HMS) and Tufts University School of Medicine.

Candidate will practice Pulmonary/CC medicine and ideally incorporate dedicated Sleep Medicine time, as well as possess a strong interest in resident and medical student teaching. Incoming physician should possess excellent clinical/communication skills and a strong commitment to serve our multicultural safety net patient population. This position has both inpatient and outpatient responsibilities. We offer a supportive and collegial environment with a strong infrastructure, inclusive of an electronic medical records system (EPIC). Candidates will have the opportunity to work in a team environment with dedicated colleagues similarly committed to providing high quality healthcare. Our employees receive competitive salary and excellent benefits.

Please send CV’s to Lauren Anastasia, Department of Physician Recruitment, Cambridge Health Alliance, 1491 Cambridge Street, Cambridge, MA 02139, via e-mail: lanastasia@challiance.org, via fax (617) 665-3553 or call (617) 665-3555. www.challiance.org.

We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status, protected veteran status, or any other characteristic protected by law.

www.challiance.org

Moving? Look to Classified Notices for practices available in your area.
Pulmonary Vascular Disease

Pulmonary Arterial Hypertension Associated With SLE

While pulmonary arterial hypertension (PAH) commonly complicates scleroderma (SSc), it is a rare complication of other connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). In the few prospective studies that utilize right-sided heart catheterization (RHC), the estimated prevalence of PAH in SLE is about 4%. However, since the prevalence of SLE is 10 to 15 times greater than SSc in the United States, the true prevalence of SLE-PAH may be higher than previously thought, and, thus, clinically relevant. Despite this, little is known about SLE-PAH.

A recent retrospective study from the French Pulmonary Hypertension Registry has added significantly to our understanding of this complication of SLE. Hachulla and colleagues studied 51 patients with RHC-proven SLE-PAH compared with 101 SLE control subjects without PAH. While the authors did not find any relevant differences in the demographics between groups, they did find a significantly higher prevalence of SSA and SSB antibodies in SLE-PAH. Interestingly, the presence of anti-U1 RNP antibody appeared to be less common in SLE-PAH patients; this lack of association is in contrast to prior studies in mixed CTD patients with anti-U1 RNP antibodies in which the prevalence of PAH can be as high as 60%. Further, none of the SLE-PAH patients demonstrated an acute response to vasodilator challenge during RHC, emphasizing that this maneuver does not need to be performed in SLE patients at risk of PAH. Trends toward improved survival in SLE-PAH patients treated with hydroxychloroquine are preliminary and hypothesis-generat-

References

Faster and even safer.

Get the same EKOS® efficacy in 1/2 the time or less, with 1/2 the dose or less. The 2017 OPTALYSE PE randomized, multi-center study showed EKOS® two, four and six-hour treatments all relieved right heart strain, with efficacy similar to EKOS® current 12/24-hour treatment and r-tPA doses as low as 4 mg per catheter.1,4 Shorter treatments give physicians same-day scheduling options and lower doses enhance safety.1

Visit www.ekoscorp.com to learn more about the only endovascular device cleared by the FDA for the treatment of pulmonary embolism.

EKOS® — Setting the standard in PE treatment.


FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is indicated for the ultrasound facilitated, controlled, and selective infusion of physician specified fluids, including thrombolitics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician specified fluids, including thrombolitics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries. Instructions for use, including warnings, precautions, potential complications, and contraindications can be found at www.ekoscorp.com. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. THE CE MARK (CE0086) HAS BEEN AFFIXED TO THE EKOSONIC® PRODUCT WITH THE FOLLOWING INDICATIONS: Peripheral Vasculature: The EkoSonic® Endovascular Device, consisting of the Intelligent Drug Delivery Catheter (IDDC) and the MicroSonic™ Device (MSD), is intended for controlled and selective infusion of physician specified fluids, including thrombolitics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic® Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent. Pulmonary Embolism: The EKOS EkoSonic® Endovascular System is intended for the treatment of pulmonary embolism patients with a 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25mmHg) or echocardiographic evaluation.